138402-11-6 | Irbesartan

Packsize	Purity	Availability	Price	Discounted Price
50mg	95%	in stock	$7.00	$5.00
100mg	95%	in stock	$9.00	$6.00
250mg	95%	in stock	$11.00	$8.00
5g	95%	in stock	$13.00	$9.00
10g	95%	in stock	$22.00	$16.00
25g	95%	in stock	$48.00	$34.00
100g	95%	in stock	$133.00	$93.00
500g	95%	in stock	$406.00	$284.00

Description

• Catalog Number: AA57766
• Chemical Name: Irbesartan
• CAS Number: 138402-11-6
• Molecular Formula: C25H28N6O
• Molecular Weight: 428.52941999999985
• MDL Number: MFCD00864464
• SMILES: CCCCC1=NC2(C(=O)N1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)CCCC2
• NSC Number: 758696

Computed Properties

• Complexity: 682
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 32
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 7
• XLogP3: 4.1

Literature

• A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

  Toxicological sciences : an official journal of the Society of Toxicology 20131101

• Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP).

  Molecular pharmaceutics 20130304

• Chemokine receptor antagonists.

  Journal of medicinal chemistry 20121126

• Clinical study of western medicine combined with Chinese medicine based on syndrome differentiation in the patients with polarized hypertension.

  Chinese journal of integrative medicine 20121001

• Irbesartan and emodin on myocardial remodeling in Goldblatt hypertensive rats.

  Journal of cardiovascular pharmacology 20121001

• [AII antagonists (candesartan and irbesartan) in the treatment of cardiovascular diseases].

  Vnitrni lekarstvi 20121001

• Multi-class determination of personal care products and pharmaceuticals in environmental and wastewater samples by ultra-high performance liquid-chromatography-tandem mass spectrometry.

  Talanta 20120915

• Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism.

  Hypertension (Dallas, Tex. : 1979) 20120901

• Anti-inflammatory drug evaluation in ApoE-/- mice by ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging.

  Investigative radiology 20120901

• Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.

  Circulation. Heart failure 20120901

• Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study.

  Journal of hypertension 20120801

• Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.

  Hypertension (Dallas, Tex. : 1979) 20120801

• Irbesartan does not influence the antiplatelet effect of aspirin in spontaneously hypertensive rats.

  CNS neuroscience & therapeutics 20120801

• Treatment of diastolic dysfunction in hypertension.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20120801

• Liquid chromatography-mass spectrometric determination of losartan and its active metabolite on dried blood spots.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120801

• I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.

  Clinical therapeutics 20120801

• I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.

  Clinical therapeutics 20120801

• Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.

  International journal of molecular medicine 20120701

• Aggressive blood pressure-lowering therapy guided by home blood pressure monitoring improves target organ damage in hypertensive patients with type 2 diabetes/prediabetes.

  Journal of clinical hypertension (Greenwich, Conn.) 20120701

• [Overexpression of angiotensin-converting enzyme 2 inhibits angiotensin II type 1 receptor expression and signal transducer and activator of transcription 3 phosphorylation in cultured smooth muscle cells].

  Zhonghua xin xue guan bing za zhi 20120701

• Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120601

• Activated plasma coagulation β-Factor XII-induced vasoconstriction in rats.

  Clinical science (London, England : 1979) 20120601

• Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling.

  Oncology reports 20120601

• Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice.

  Hypertension (Dallas, Tex. : 1979) 20120601

• Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis.

  Circulation research 20120511

• Mechanical load-dependent cardiac ER stress in vitro and in vivo: effects of preload and afterload.

  FEBS letters 20120507

• Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.

  Amino acids 20120501

• Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120501

• AT1 receptor blockade delays postlactational mammary gland involution: a novel role for the renin angiotensin system.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20120501

• Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.

  American journal of hypertension 20120501

• An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials.

  Journal of hypertension 20120501

• Antihypertensive drugs in patients treated with antiretrovirals.

  The Annals of pharmacotherapy 20120501

• Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure.

  Acta pharmacologica Sinica 20120501

• Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect.

  Bioorganic & medicinal chemistry 20120415

• The 'missing' link between acute hemodynamic effect and clinical response.

  Journal of cardiovascular translational research 20120401

• Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.

  The American journal of cardiology 20120401

• Comparative effectiveness of incident oral antidiabetic drugs on kidney function.

  Kidney international 20120401

• The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP.

  Scandinavian journal of clinical and laboratory investigation 20120401

• Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan.

  Journal of thrombosis and haemostasis : JTH 20120401

• Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events.

  Circulation. Cardiovascular genetics 20120401

• Angiogenesis related gene expression profiles of EA.hy926 cells induced by irbesartan: a possible novel therapeutic approach.

  Chinese medical journal 20120401

• Simultaneous analysis of irbesartan and hydrochlorothiazide: an improved HPLC method with the aid of a chemometric protocol.

  Molecules (Basel, Switzerland) 20120316

• Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study.

  International journal of cardiology 20120308

• The beneficial effects of nebivolol on endothelial functions in arterial hypertension.

  International journal of cardiology 20120308

• Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.

  Pharmacoepidemiology and drug safety 20120301

• Abilities of candesartan and other AT(1) receptor blockers to impair angiotensin II-induced AT(1) receptor activation after wash-out.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20120301

• Spectrofluorimetric determination of aliskiren in tablets and spiked human plasma through derivatization with dansyl chloride.

  Journal of fluorescence 20120301

• Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury.

  Pharmacological research 20120301

• Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.

  Diabetologia 20120301

• Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.

  Circulation. Heart failure 20120301

• Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.

  Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20120301

• Still at the drawing board: improving quality of life in heart failure.

  Circulation. Heart failure 20120301

• Use of direct renin inhibitor in an HIV positive subject.

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20120301

• Inhibition of integrin-linked kinase by angiotensin II receptor antagonist, irbesartan attenuates podocyte injury in diabetic rats.

  Chinese medical journal 20120301

• Subtle issues in model specification and estimation of marginal structural models.

  Pharmacoepidemiology and drug safety 20120301

• Influence of irbesartan on the urinary excretion of cytokines in patients with chronic kidney disease.

  Chinese medical journal 20120301

• The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review.

  High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 20120301

• [Protective effects of compound shenhua tablet on diabetic nephropathy rats].

  Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20120301

• Vitamin D: a novel player in endothelial function and dysfunction.

  Archives of medical science : AMS 20120227

• Hydrophilic interaction chromatography-electrospray ionization tandem mass spectrometric analysis of anastrozole in human plasma and its application to a pharmacokinetic study.

  Biomedical chromatography : BMC 20120201

• CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.

  European journal of clinical pharmacology 20120201

• Role of brainstem thyrotropin-releasing hormone-triggered sympathetic overactivation in cardiovascular mortality in type 2 diabetic Goto-Kakizaki rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120201

• A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.

  International journal of stroke : official journal of the International Stroke Society 20120201

• Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120201

• Novel mechanism of angiotensin II-induced cardiac injury in hypertensive rats: the critical role of ASK1 and VEGF.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120201

• [Triptolide combined with irbesartan synergistically blocks podocyte injury in a type 2 diabetes rat model].

  Zhonghua nei ke za zhi 20120201

• Beneficial effect of traditional chinese medicinal formula danggui-shaoyao-san on advanced glycation end-product-mediated renal injury in streptozotocin-diabetic rats.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101

• Cardiac insulin resistance and microRNA modulators.

  Experimental diabetes research 20120101

• The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial.

  The Canadian journal of cardiology 20120101

• Do aspirin and other antiplatelet drugs reduce the mortality in critically ill patients?

  Thrombosis 20120101

• [Leukoneutropenia associated with irbesartan].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20120101

• Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension.

  Journal of hypertension 20120101

• Early experience using a left atrial appendage occlusion device in patients with atrial fibrillation.

  Yonsei medical journal 20120101

• A Novel Cellular Model to Study Angiotensin II AT2 Receptor Function in Breast Cancer Cells.

  International journal of peptides 20120101

• The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis.

  BMJ (Clinical research ed.) 20120101

• Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study.

  BMJ (Clinical research ed.) 20120101

• Safety and efficacy of rituximab treatment for vasculitis in hepatitis B virus-associated type II cryoglobulinemia: a case report.

  Journal of medical case reports 20120101

• Effect of an Oral Adsorbent, AST-120, on Dialysis Initiation and Survival in Patients with Chronic Kidney Disease.

  International journal of nephrology 20120101

• Kidney disease and youth onset type 2 diabetes: considerations for the general practitioner.

  International journal of pediatrics 20120101

• New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis.

  International journal of hypertension 20120101

• Online availability and safety of drugs in shortage: a descriptive study of internet vendor characteristics.

  Journal of medical Internet research 20120101

• New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.

  Vascular health and risk management 20120101

• Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.

  Journal of neuroinflammation 20120101

• Impact of macrophage inflammatory protein-1α deficiency on atherosclerotic lesion formation, hepatic steatosis, and adipose tissue expansion.

  PloS one 20120101

• Ameliorating effects of two extracts of Nigella sativa in middle cerebral artery occluded rat.

  Journal of pharmacy & bioallied sciences 20120101

• Differential pharmacology and benefit/risk of azilsartan compared to other sartans.

  Vascular health and risk management 20120101

• Stroke Prevention in Atrial Fibrillation: Where are We Now?

  Clinical Medicine Insights. Cardiology 20120101

• Therapeutic options for the treatment of hypertension in children and adolescents.

  Clinical medicine insights. Circulatory, respiratory and pulmonary medicine 20120101

• Sex differences in primary hypertension.

  Biology of sex differences 20120101

• High doses of irbesartan offer long-term kidney protection in cases of established diabetic nephropathy.

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20120101

• New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil.

  Integrated blood pressure control 20120101

• Strategies to reverse endothelial progenitor cell dysfunction in diabetes.

  Experimental diabetes research 20120101

• The effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients.

  International journal of vascular medicine 20120101

• What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?

  Cardiovascular diabetology 20120101

• [Effect of irbesartan on the proliferation, apoptosis and VEGF mRNA expression of human umbilical vein cell line ea. hy926 in vitro].

  Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 20120101

• Are verbal fluency and nonliteral language comprehension deficits related to depressive symptoms in Parkinson's disease?

  Parkinson's disease 20120101

• [Clinical observation of treating early diabetic nephropathy by qi supplementing, yin nourishing, blood stasis dispersing, collateral dredging recipe].

  Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20120101

• Natriuretic peptides for the detection of paroxysmal atrial fibrillation in patients with cerebral ischemia--the Find-AF study.

  PloS one 20120101

• Spontaneous splenic rupture and Anisakis appendicitis presenting as abdominal pain: a case report.

  Journal of medical case reports 20120101

• Nonarteritic anterior ischemic optic neuropathy and double thrombophilic defect: a new observation.

  Case reports in ophthalmology 20120101

• Cardiac myosin binding protein C and MAP-kinase activating death domain-containing gene polymorphisms and diastolic heart failure.

  PloS one 20120101

• Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database.

  BMJ (Clinical research ed.) 20120101

• Emerging drug combinations to optimize renovascular protection and blood pressure goals.

  International journal of nephrology and renovascular disease 20120101

• Angiotensin II facilitates breast cancer cell migration and metastasis.

  PloS one 20120101

• Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes.

  PloS one 20120101

• Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study).

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101

• Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants.

  Journal of blood medicine 20120101

• Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease.

  Thrombosis 20120101

• Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20120101

• Oxidative stress and heart failure in altered thyroid States.

  TheScientificWorldJournal 20120101

• Critical evaluation of the efficacy and tolerability of azilsartan.

  Vascular health and risk management 20120101

• Mass spectrometry for diabetic nephropathy monitoring: new effective tools for physicians.

  ISRN endocrinology 20120101

• ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production.

  PloS one 20120101

• Antioxidants in kidney diseases: the impact of bardoxolone methyl.

  International journal of nephrology 20120101

• Irbesartan prevents myocardial remodeling in experimental thyrotoxic cardiomyopathy.

  Endocrine journal 20120101

• Angiotensin II protects primary rat hepatocytes against bile salt-induced apoptosis.

  PloS one 20120101

• Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction.

  Circulation 20111206

• Funny turn.

  BMJ (Clinical research ed.) 20111205

• Blood pressure telemonitoring is useful to achieve blood pressure control in inadequately treated patients with arterial hypertension.

  Journal of human hypertension 20111201

• The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy.

  Acta histochemica 20111201

• Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.

  Diabetologia 20111201

• Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?

  Journal of hypertension 20111201

• Nifedipine and telmisartan for the treatment of hypertension: the TALENT study.

  Expert review of cardiovascular therapy 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Prediction of drug combinations by integrating molecular and pharmacological data.

  PLoS computational biology 20111201

• [The efficacy and safety of high-dose irbesartan in treatment of clinical proteinuria in patients with chronic kidney disease].

  Zhonghua nei ke za zhi 20111201

• Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction.

  Heart and vessels 20111101

• Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20111101

• Preparation of stable micron-sized crystalline irbesartan particles for the enhancement of dissolution rate.

  Drug development and industrial pharmacy 20111101

• Genetic determinants of platelet response to clopidogrel.

  Journal of thrombosis and thrombolysis 20111101

• Rationale and current perspective for early rhythm control therapy in atrial fibrillation.

  Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20111101

• The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain.

  Hypertension research : official journal of the Japanese Society of Hypertension 20111101

• Evaluation of a direct prorenin assay making use of a monoclonal antibody directed against residues 32-39 of the prosegment.

  Journal of hypertension 20111101

• Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.

  Annals of internal medicine 20111101

• Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.

  Journal of clinical hypertension (Greenwich, Conn.) 20111101

• [Irbesartan regulates inflammatory gene expressions related to atherosclerosis in EA.hy926 cells].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20111101

• Erythema gyratum repens: a rare paraneoplastic rash.

  The western journal of emergency medicine 20111101

• Do genetic variants of the Renin-Angiotensin system predict blood pressure response to Renin-Angiotensin system-blocking drugs?: a systematic review of pharmacogenomics in the Renin-Angiotensin system.

  Current hypertension reports 20111001

• Pharmacotherapy review of chronic pediatric hypertension.

  Clinical therapeutics 20111001

• Optimal antithrombotic strategy in patients with atrial fibrillation after coronary stent implantation.

  Korean circulation journal 20111001

• Mineralocorticoid hypertension.

  Indian journal of endocrinology and metabolism 20111001

• Management of diabetic hypertensives.

  Indian journal of endocrinology and metabolism 20111001

• NIR analysis of pharmaceutical samples without reference data: improving the calibration.

  Talanta 20110930

• Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20110901

• Spectroscopic and spectrofluorimetric studies on the interaction of irbesartan with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and iodine.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20110901

• Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.

  Cancer chemotherapy and pharmacology 20110901

• Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.

  Circulation. Heart failure 20110901

• Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.

  Circulation. Heart failure 20110901

• Long-term clinical and economic outcomes associated with angiotensin II receptor blocker use in hypertensive patients.

  Current medical research and opinion 20110901

• initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial.

  Diabetes care 20110901

• Synergism of irbesartan and amlodipine on hemodynamic amelioration and organ protection in spontaneously hypertensive rats.

  Acta pharmacologica Sinica 20110901

• Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.

  Clinical therapeutics 20110901

• Compliance, persistence, and switching patterns for ACE inhibitors and ARBs.

  The American journal of managed care 20110901

• Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease.

  Circulation. Heart failure 20110901

• Photodistributed telangiectasia induced by amlodipine.

  Annals of dermatology 20110901

• Blockade of angiotensin II improves hyperthyroid induced abnormal atrial electrophysiological properties.

  Regulatory peptides 20110808

• Aldosterone induction of hepatic stellate cell contraction through activation of RhoA/ROCK-2 signaling pathway.

  Regulatory peptides 20110808

• Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/ Rho kinase pathways targeted to lipid rafts.

  Arteriosclerosis, thrombosis, and vascular biology 20110801

• Role of irbesartan in prevention of post-coronary artery bypass graft atrial fibrillation.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20110801

• Novel mechanism of salt-induced glomerular injury: critical role of eNOS and angiotensin II.

  Journal of hypertension 20110801

• [Activation of Rho-kinase pathway is involved in angiotensin II-induced contraction of human airway smooth muscle cells].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20110801

• Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide-deficient rats.

  Clinics (Sao Paulo, Brazil) 20110801

• Prevalence, Awareness, and Control of Hypertension among Diabetic Koreans.

  Diabetes & metabolism journal 20110801

• Primary stroke prevention and hypertension treatment: which is the first-line strategy?

  Neurology international 20110705

• Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individuals.

  Microvascular research 20110701

• The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer.

  European journal of cancer (Oxford, England : 1990) 20110701

• A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.

  Postgraduate medicine 20110701

• [Effect of different combined antihypertensive regimen on the erectile function in male hypertensive patients].

  Zhonghua xin xue guan bing za zhi 20110701

• [Irbesartan does not reduce the rate of cardiovascular events in patients with atrial fibrillation].

  Praxis 20110608

• Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT₁ receptor blockade.

  Biochemical and biophysical research communications 20110603

• Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.

  The European journal of health economics : HEPAC : health economics in prevention and care 20110601

• A population-based survey of Chronic REnal Disease In Turkey--the CREDIT study.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110601

• Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂.

  Metabolic syndrome and related disorders 20110601

• Genetics of mechanosensation in the heart.

  Journal of cardiovascular translational research 20110601

• Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.

  European heart journal 20110601

• Angiotensin II type 1 receptor blockade does not enhance apoptotic cell death during ischemia and reperfusion in humans in vivo.

  Journal of cardiovascular pharmacology 20110601

• The unmet need of patients with atrial fibrillation: AVERROES and the novel oral anticoagulants.

  International journal of stroke : official journal of the International Stroke Society 20110601

• Autonomic imbalance: prophet of doom or scope for hope?

  Diabetic medicine : a journal of the British Diabetic Association 20110601

• Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?

  Mayo Clinic proceedings 20110601

• [Transforming growth factor-β1 regulates renal α3 and β1 integrin expressions in diabetic rats: a new insight into the renoprotective effect of irbesartan].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20110601

• Epigallocatechin-3-gallate Regulates Inducible Nitric Oxide Synthase Expression in Human Umbilical Vein Endothelial Cells.

  Laboratory animal research 20110601

• Inulin and poly(acrylic acid) grafted inulin for dissolution enhancement and preliminary controlled release of poorly water-soluble Irbesartan drug.

  International journal of pharmaceutics 20110530

• Protective effect of irbesartan, an angiotensin II receptor antagonist, alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats.

  Human & experimental toxicology 20110501

• Effects of protein coding polymorphisms in the kallikrein 1 gene on baseline blood pressure and antihypertensive response to irbesartan in Chinese hypertensive patients.

  Journal of human hypertension 20110501

• Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells.

  Microvascular research 20110501

• Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS).

  Diabetologia 20110501

• Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials.

  American journal of hypertension 20110501

• CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.

  Drug metabolism and disposition: the biological fate of chemicals 20110501

• Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan.

  Journal of hypertension 20110501

• Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.

  Circulation. Heart failure 20110501

• Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy.

  Diabetes care 20110501

• Risk-benefit ratio assessment for stroke prevention in intermediate risk atrial fibrillation patients: will TEE-based aspirin treatment fill the gap?

  Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 20110501

• Vitamin D levels, microvascular complications, and mortality in type 1 diabetes.

  Diabetes care 20110501

• [Production of connective tissue growth factor by angiotensin II in human embryonic lung fibroblast via RhoA-ROCK pathway].

  Zhonghua yi xue za zhi 20110426

• The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics.

  Journal of human hypertension 20110401

• Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications.

  American journal of hypertension 20110401

• Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.

  Cardiovascular research 20110401

• Local and systemic effects of angiotensin receptor blockade in an emphysema mouse model.

  Pulmonary pharmacology & therapeutics 20110401

• 20-Hydroxyeicosatetraenoic acid synthesis is increased in human neutrophils and platelets by angiotensin II and endothelin-1.

  American journal of physiology. Heart and circulatory physiology 20110401

• Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.

  Journal of hypertension 20110401

• Cryoglobulinemic membranoproliferative glomerulonephritis: beyond conventional therapy.

  Clinical nephrology 20110401

• Treatment of long-lasting persistent atrial fibrillation using minimally invasive surgery combined with irbesartan.

  The Annals of thoracic surgery 20110401

• Invited commentary.

  The Annals of thoracic surgery 20110401

• Atrial fibrillation, is warfarin the only option for stroke prevention?

  JPMA. The Journal of the Pakistan Medical Association 20110401

• Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model.

  Diabetes & metabolism journal 20110401

• Electrochemical determination of antihypertensive drug irbesartan in pharmaceuticals.

  Analytical biochemistry 20110315

• Exploring the mechanisms of renoprotection against progressive glomerulosclerosis.

  Proceedings of the Japan Academy. Series B, Physical and biological sciences 20110311

• Irbesartan in patients with atrial fibrillation.

  The New England journal of medicine 20110310

• Irbesartan increased PPARγ activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction.

  Biochemical and biophysical research communications 20110304

• Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome.

  Journal of human hypertension 20110301

• In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies.

  The Journal of pharmacology and experimental therapeutics 20110301

• Functional sympatholysis is impaired in hypertensive humans.

  The Journal of physiology 20110301

• Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.

  The American journal of the medical sciences 20110301

• Improvement of coronary microvascular function after Angiotensin receptor blocker treatment with irbesartan in patients with systemic hypertension.

  Journal of clinical hypertension (Greenwich, Conn.) 20110301

• Atrial fibrillation, is warfarin the only option for stroke prevention?

  JPMA. The Journal of the Pakistan Medical Association 20110301

• Depressogenic effects of medications: a review.

  Dialogues in clinical neuroscience 20110301

• Enalapril, irbesartan, and angiotensin-(1-7) prevent atrial tachycardia-induced ionic remodeling.

  International journal of cardiology 20110203

• Effect of renal sympathetic nerve on adrenergically and angiotensin II-induced renal vasoconstriction in normal Wistar-Kyoto rats.

  Upsala journal of medical sciences 20110201

• Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110201

• Treatment of heart failure with normal ejection fraction.

  Current treatment options in cardiovascular medicine 20110201

• Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension.

  American journal of physiology. Heart and circulatory physiology 20110201

• Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril.

  International journal of clinical practice 20110201

• Quantitation of irbesartan and major proteins in human plasma by mass spectrometry with time-of-flight analyzer.

  Journal of pharmaceutical and biomedical analysis 20110105

• Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

  Diabetologia 20110101

• Effect of adding pharmacists to primary care teams on blood pressure control in patients with type 2 diabetes: a randomized controlled trial.

  Diabetes care 20110101

• Platelet activation in hypertension associated with hypercholesterolemia: effects of irbesartan.

  Journal of thrombosis and haemostasis : JTH 20110101

• Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).

  Circulation. Heart failure 20110101

• Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20110101

• Integrative bioinformatics analysis of proteins associated with the cardiorenal syndrome.

  International journal of nephrology 20110101

• Standards of medical care in diabetes--2011.

  Diabetes care 20110101

• Internet-based treatment for older adults with depression and co-morbid cardiovascular disease: protocol for a randomised, double-blind, placebo controlled trial.

  BMC psychiatry 20110101

• Treatment with a corticotrophin releasing factor 2 receptor agonist modulates skeletal muscle mass and force production in aged and chronically ill animals.

  BMC musculoskeletal disorders 20110101

• Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study.

  Cardiovascular diabetology 20110101

• Low-molecular-weight heparin successfully used to treat a nephrotic patient complicated by superior mesenteric vein thrombosis and portal vein thrombosis.

  Medical principles and practice : international journal of the Kuwait University, Health Science Centre 20110101

• Pharmacological and non-pharmacological interventions to influence adipose tissue function.

  Cardiovascular diabetology 20110101

• Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study.

  BMJ (Clinical research ed.) 20110101

• Cardiorenal syndrome caused by heart failure with preserved ejection fraction.

  International journal of nephrology 20110101

• Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.

  P & T : a peer-reviewed journal for formulary management 20110101

• Sex differences in drug disposition.

  Journal of biomedicine & biotechnology 20110101

• Renal protection with angiotensin receptor blockers: where do we stand.

  Journal of nephrology 20110101

• [Rapidly progressive renal failure as the onset of an IgA nephropathy in an elderly patient].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20110101

• Solubility, dissolution rate and bioavailability enhancement of irbesartan by solid dispersion technique.

  Chemical & pharmaceutical bulletin 20110101

• Olmesartan medoxomil for the treatment of hypertension in children and adolescents.

  Vascular health and risk management 20110101

• Olmesartan/amlodipine: a review of its use in the management of hypertension.

  Vascular health and risk management 20110101

• Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials.

  BMJ (Clinical research ed.) 20110101

• Clinical utility of valsartan in the treatment of hypertension in children and adolescents.

  Patient preference and adherence 20110101

• Atrial Fibrillation Ablation without Interruption of Anticoagulation.

  Cardiology research and practice 20110101

• Pharmacological management of atrial fibrillation: one, none, one hundred thousand.

  Cardiology research and practice 20110101

• Study protocol: the DESPATCH study: delivering stroke prevention for patients with atrial fibrillation - a cluster randomised controlled trial in primary healthcare.

  Implementation science : IS 20110101

• Cardiovascular and Renal Links along the Cardiorenal Continuum.

  International journal of nephrology 20110101

• Combination delapril/manidipine as antihypertensive therapy in high-risk patients.

  Clinical drug investigation 20110101

• Reappraisal of role of angiotensin receptor blockers in cardiovascular protection.

  Vascular health and risk management 20110101

• A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.

  Vascular health and risk management 20110101

• Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy.

  PloS one 20110101

• Aliskiren: An orally active renin inhibitor.

  Journal of pharmacy & bioallied sciences 20110101

• Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ.

  Journal of pharmacological sciences 20110101

• Diabetic microvascular complications: possible targets for improved macrovascular outcomes.

  International journal of nephrology and renovascular disease 20110101

• Hypertension, poor glycemic control, and microalbuminuria in Cuban Americans with type 2 diabetes.

  International journal of nephrology and renovascular disease 20110101

• Role of aliskiren in blood pressure control and renoprotection.

  International journal of nephrology and renovascular disease 20110101

• Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation.

  BMC cancer 20110101

• Hypertension in chronic kidney disease: navigating the evidence.

  International journal of hypertension 20110101

• Endothelin but Not Angiotensin II May Mediate Hypertension-Induced Coronary Vascular Calcification in Chronic Kidney Disease.

  International journal of nephrology 20110101

• Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptidey levels in patients with type 2 diabetes mellitus: a pilot study.

  The open cardiovascular medicine journal 20110101

• Diabetic nephropathy - Epidemiology in Asia and the current state of treatment.

  Indian journal of nephrology 20110101

• Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

  The open cardiovascular medicine journal 20110101

• Antiplatelets in secondary stroke prevention.

  Frontiers in neurology 20110101

• Severe Hypocalcemia due to Vitamin D Deficiency after Extended Roux-en-Y Gastric Bypass.

  Journal of obesity 20110101

• Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.

  BMJ (Clinical research ed.) 20110101

• Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women.

  International journal of women's health 20110101

• Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective.

  Thrombosis journal 20110101

• Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials.

  Vascular health and risk management 20110101

• Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.

  Vascular health and risk management 20110101

• Antithrombotic medication for cardioembolic stroke prevention.

  Stroke research and treatment 20110101

• Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study.

  Cardiovascular diabetology 20110101

• 3',4'-Dihydroxyflavonol antioxidant attenuates diastolic dysfunction and cardiac remodeling in streptozotocin-induced diabetic m(Ren2)27 rats.

  PloS one 20110101

• Management of patients with atrial fibrillation: specific considerations for the old age.

  Cardiology research and practice 20110101

• Inflammatory myopathy and severe rhabdomyolysis induced by leuprolide acetate therapy for prostate cancer: a case report.

  Journal of medical case reports 20110101

• Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis.

  International journal of biological sciences 20110101

• Long-term use and tolerability of irbesartan for control of hypertension.

  Integrated blood pressure control 20110101

• Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model.

  PloS one 20110101

• Pre-implant right ventricular function might be an important predictor of the response to cardiac resynchronization therapy.

  Cardiovascular ultrasound 20110101

• Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk.

  Vascular health and risk management 20110101

• Identification and determination of selected angiotensin II receptor antagonist group drugs by HPLC method.

  Acta poloniae pharmaceutica 20110101

• Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure.

  BMC cardiovascular disorders 20110101

• Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan.

  Journal of advanced pharmaceutical technology & research 20110101

• Clinical and functional characterization of URAT1 variants.

  PloS one 20110101

• Antihypertensive treatment differentially affects vascular sphingolipid biology in spontaneously hypertensive rats.

  PloS one 20110101

• Critical review of cancer risk associated with angiotensin receptor blocker therapy.

  Vascular health and risk management 20110101

• Differential clinical profile of candesartan compared to other angiotensin receptor blockers.

  Vascular health and risk management 20110101

• Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination.

  Integrated blood pressure control 20110101

• Novel Pharmacological Interventions to Maintain Sinus Rhythm after DC Cardioversion.

  ISRN cardiology 20110101

• Renoprotective effects of combining ACE inhibitors and statins in experimental diabetic rats.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101

• Irbesartan enhances GLUT4 translocation and glucose transport in skeletal muscle cells.

  European journal of pharmacology 20101215

• Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.

  Bioorganic & medicinal chemistry 20101215

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• The angiotensin II receptor type 2 polymorphism influences haemodynamic function and circulating RAS mediators in normotensive humans.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20101201

• Follow-up of cardiovascular risk markers in hypertensive patients treated with irbesartan: results of the i-SEARCH Plus Registry.

  Journal of clinical hypertension (Greenwich, Conn.) 20101201

• Remodeling of ion channel expression in patients with chronic atrial fibrillation and mitral valvular heart disease.

  The Korean journal of internal medicine 20101201

• Effect of Lacidipine on Blood Pressure and Endothelial Function in Mild-to-Moderate Essential Hypertension Patients With Diabetes in Korea.

  Korean circulation journal 20101201

• Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.

  Healthcare informatics research 20101201

• Rhabdomyolysis associated with phentermine.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20101115

• Effects of angiotensin type 1 receptor blockade on arginine and ADMA synthesis and metabolic pathways in fawn-hooded hypertensive rats.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20101101

• Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.

  Diabetes care 20101101

• Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals.

  Journal of hypertension 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• The cardiac renin-angiotensin system is responsible for high-salt diet-induced left ventricular hypertrophy in mice.

  European journal of heart failure 20101101

• Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study.

  Journal of mass spectrometry : JMS 20101101

• Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension.

  Drugs 20101022

• [Video-assisted minimally invasive radiofrequency ablation in the treatment of persistent atrial fibrillation].

  Zhonghua wai ke za zhi [Chinese journal of surgery] 20101015

• Neurological picture. Orolingual angio-oedema after alteplase therapy in a stroke patient concurrently using angiotensin II receptor blocker.

  Journal of neurology, neurosurgery, and psychiatry 20101001

• Angiotensin II contributes to the increased baseline leg vascular resistance in spinal cord-injured individuals.

  Journal of hypertension 20101001

• Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.

  Journal of hypertension 20101001

• A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects.

  Hypertension research : official journal of the Japanese Society of Hypertension 20101001

• Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy.

  Diabetes 20101001

• Effects of bisoprolol and cilazapril on the central retinal artery blood flow in patients with essential hypertension--preliminary results.

  Upsala journal of medical sciences 20101001

• Sitagliptin-induced hemolysis.

  Indian journal of pharmacology 20101001

• Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20100901

• Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats.

  Diabetologia 20100901

• Stretch-induced hypertrophy of isolated adult rabbit cardiomyocytes.

  American journal of physiology. Heart and circulatory physiology 20100901

• Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?

  The American journal of medicine 20100901

• Combination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacement.

  Circulation journal : official journal of the Japanese Circulation Society 20100901

• Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement.

  Current medical research and opinion 20100901

• Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.

  European heart journal 20100901

• Effectiveness, safety and cost of drug substitution in hypertension.

  British journal of clinical pharmacology 20100901

• Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event rates.

  The American journal of cardiology 20100901

• Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.

  European review for medical and pharmacological sciences 20100901

• Abstracts of the 5(th) Cachexia Conference, Barcelona, Spain, December 5-8, 2009.

  Journal of cachexia, sarcopenia and muscle 20100901

• Mast cell degranulation mediates bronchoconstriction via serotonin and not via renin release.

  European journal of pharmacology 20100825

• Definitions and incidence of cardiac syndrome X: review and analysis of clinical data.

  Clinical research in cardiology : official journal of the German Cardiac Society 20100801

• Persistent correction of hyperglycemia in streptozotocin-nicotinamide-induced diabetic mice by a non-conventional radical scavenger.

  Naunyn-Schmiedeberg's archives of pharmacology 20100801

• Drug mechanisms to help in managing resistant hypertension in obesity.

  Current hypertension reports 20100801

• Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia.

  British journal of pharmacology 20100801

• Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review.

  Diabetes care 20100801

• Point: postprandial glucose levels are a clinically important treatment target.

  Diabetes care 20100801

• Stability indicating LC method for simultaneous determination of irbesartan and hydrochlorothiazide in pharmaceutical preparations.

  Journal of chromatographic science 20100801

• [Effect between felodipine plus irbesartan and felodipine plus metoprolol regimen on the sexual function in young and middle-aged women with hypertension].

  Zhonghua xin xue guan bing za zhi 20100801

• Antithrombotic therapy in cardiac embolism.

  Current cardiology reviews 20100801

• Diastolic function measurements and diagnostic consequences: a comparison of pulsed wave- and color-coded tissue Doppler imaging.

  Clinical research in cardiology : official journal of the German Cardiac Society 20100701

• A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy.

  Diabetes care 20100701

• Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors.

  Journal of clinical hypertension (Greenwich, Conn.) 20100701

• Integrated control of pulmonary vascular tone by endothelin and angiotensin II in exercising swine depends on gender.

  American journal of physiology. Heart and circulatory physiology 20100601

• Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis.

  Diabetologia 20100601

• Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension.

  Current medical research and opinion 20100601

• A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.

  Pharmacogenetics and genomics 20100601

• Update on antithrombotic therapy for stroke prevention in atrial fibrillation.

  Current treatment options in cardiovascular medicine 20100601

• [Effect of irbesartan on ACE2 expression in diabetic rat myocardium].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100601

• Irbesartan in experimental diabetic nephropathy.

  Indian journal of pharmacology 20100601

• Authors' reply.

  Indian journal of pharmacology 20100601

• Colloid formation by drugs in simulated intestinal fluid.

  Journal of medicinal chemistry 20100527

• Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers.

  Arthritis and rheumatism 20100501

• Cognitive function and anticoagulation control in patients with atrial fibrillation.

  Circulation. Cardiovascular quality and outcomes 20100501

• Does irbesartan improve the risk of death or hospitalization for cardiovascular causes among patients with HF and PEF?

  Current cardiology reports 20100501

• Protective effects of irbesartan and alpha lipoic acid in STZ-induced diabetic nephropathy in rats.

  Renal failure 20100501

• [Dose-effect relationship of irbsartan with the changes in the renal tissue structure in diabetic rats].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100501

• Intestinal schistosomiasis caused by both Schistosoma intercalatum and Schistosoma mansoni.

  Travel medicine and infectious disease 20100501

• Diabetic nephropathy and chronic kidney disease at a busy diabetes clinic: a study of outpatient care and suggestions for improved care pathways at a subspecialty specialist diabetic renal clinic.

  The Ulster medical journal 20100501

• Identification and characterization of degradation products of irbesartan using LC-MS/TOF, MS(n), on-line H/D exchange and LC-NMR.

  Journal of pharmaceutical and biomedical analysis 20100406

• Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.

  Journal of human hypertension 20100401

• Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.

  European heart journal 20100401

• Response of cardiac sympathetic nerve activity to intravenous irbesartan in heart failure.

  American journal of physiology. Regulatory, integrative and comparative physiology 20100401

• Serological predictors for the recurrence of atrial fibrillation after electrical cardioversion.

  Korean circulation journal 20100401

• [Effects of Shenkangwan on renal expressions of angiotensin II and its type I receptor in rats with early diabetic nephropathy].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100401

• Application of direct renin inhibition to chronic kidney disease.

  Cardiovascular drugs and therapy 20100401

• Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.

  Diabetic medicine : a journal of the British Diabetic Association 20100401

• Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial.

  Circulation 20100330

• Is addition of angiotensin receptor blockade superior to increasing ACE inhibitor dose in patients with heart failure?

  International journal of cardiology 20100318

• Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma using HPLC coupled with tandem mass spectrometry: Application to bioequivalence studies.

  Journal of pharmaceutical and biomedical analysis 20100311

• Molecular mechanisms of irbesartan suppressing atherosclerosis in high cholesterol-diet apolipoprotein E knock-out mice.

  International journal of cardiology 20100304

• Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.

  American journal of physiology. Renal physiology 20100301

• Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.

  Expert opinion on pharmacotherapy 20100301

• Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.

  Journal of hypertension 20100301

• Blood pressure and diabetic nephropathy.

  Diabetes care 20100301

• The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.

  Journal of cardiac failure 20100301

• Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.

  Biopharmaceutics & drug disposition 20100301

• Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.

  Clinical therapeutics 20100301

• Methods of evaluation of autonomic nervous system function.

  Archives of medical science : AMS 20100301

• Autoimmune hypothyroidism and lupus-like syndrome.

  Rheumatology international 20100201

• Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.

  Journal of human hypertension 20100201

• Effects of walnut consumption on endothelial function in type 2 diabetic subjects: a randomized controlled crossover trial.

  Diabetes care 20100201

• Human recombinant ACE2 reduces the progression of diabetic nephropathy.

  Diabetes 20100201

• The efficacy and safety of irbesartan in primary hypertension even if a dose is missed: Results from the NO PROBLEM Study.

  Blood pressure. Supplement 20100201

• Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation.

  Hypertension (Dallas, Tex. : 1979) 20100201

• Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.

  Journal of cardiac failure 20100201

• [Upstream approach for atrial fibrillation].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100201

• Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20100201

• Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.

  Cardiovascular drugs and therapy 20100201

• Angiotensin II receptor blocker add-on therapy for low cardiac output in decompensated heart failure.

  Arquivos brasileiros de cardiologia 20100201

• Angina in Women without Obstructive Coronary Artery Disease.

  Current cardiology reviews 20100201

• Are there effects of renin-angiotensin system antagonists beyond blood pressure control?

  The American journal of cardiology 20100104

• Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes.

  Life sciences 20100102

• Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression.

  Pharmacological research 20100101

• Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain.

  Metabolism: clinical and experimental 20100101

• Basophil activation in two cases of hydrochlorothiazide-induced noncardiogenic pulmonary edema.

  Allergy 20100101

• Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials.

  Hypertension (Dallas, Tex. : 1979) 20100101

• Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND).

  International journal of clinical practice 20100101

• The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin-angiotensin system in diet-induced hypercholesterolemic rats.

  Cell biochemistry and function 20100101

• Standards of medical care in diabetes--2010.

  Diabetes care 20100101

• Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis.

  BMJ (Clinical research ed.) 20100101

• Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

• Irbesartan inhibits albumin-elicited proximal tubular cell apoptosis and injury in vitro.

  Protein and peptide letters 20100101

• Modern role for clopidogrel in management of atrial fibrillation and stroke reduction.

  Vascular health and risk management 20100101

• Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism.

  Patient preference and adherence 20100101

• Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure.

  PloS one 20100101

• Angiotensin II inhibits insulin-stimulated GLUT4 translocation and Akt activation through tyrosine nitration-dependent mechanisms.

  PloS one 20100101

• The role of renin angiotensin system inhibition in kidney repair.

  Fibrogenesis & tissue repair 20100101

• New standards in hypertension and cardiovascular risk management: focus on telmisartan.

  Vascular health and risk management 20100101

• Prevalence and risk factors of microalbuminuria in Thai nondiabetic hypertensive patients.

  Vascular health and risk management 20100101

• From design to implementation--the Joint Asia Diabetes Evaluation (JADE) program: a descriptive report of an electronic web-based diabetes management program.

  BMC medical informatics and decision making 20100101

• The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat.

  Mediators of inflammation 20100101

• Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study.

  Cardiovascular diabetology 20100101

• HIV protease inhibitors activate the adipocyte renin angiotensin system.

  Antiviral therapy 20100101

• Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?

  Clinical interventions in aging 20100101

• Urinary pigment epithelium-derived factor as a marker of diabetic nephropathy.

  American journal of nephrology 20100101

• Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalence.

  Vascular health and risk management 20100101

• Use of evidence-based pharmacotherapy after myocardial infarction in Estonia.

  BMC public health 20100101

• Combination therapy in hypertension: An update.

  Diabetology & metabolic syndrome 20100101

• Degradation kinetics of benzyl nicotinate in aqueous solution.

  Indian journal of pharmaceutical sciences 20100101

• Spectrophotometric and HPLC methods for simultaneous estimation of amlodipine besilate, losartan potassium and hydrochlorothiazide in tablets.

  Indian journal of pharmaceutical sciences 20100101

• PPARs in the Renal Regulation of Systemic Blood Pressure.

  PPAR research 20100101

• Angiotensin II mediates the high-glucose-induced endothelial-to-mesenchymal transition in human aortic endothelial cells.

  Cardiovascular diabetology 20100101

• The tsim tsoum approaches for prevention of cardiovascular disease.

  Cardiology research and practice 20100101

• The different isoforms of the receptor for advanced glycation end products are modulated by pharmacological agents.

  Clinical hemorheology and microcirculation 20100101

• Advanced glycation end products, oxidative stress and diabetic nephropathy.

  Oxidative medicine and cellular longevity 20100101

• Principal component analysis of HPLC retention data and molecular modeling structural parameters of cardiovascular system drugs in view of their pharmacological activity.

  International journal of molecular sciences 20100101

• Prevention strategies for cardioembolic stroke: present and future perspectives.

  The open neurology journal 20100101

• Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection.

  Vascular health and risk management 20100101

• Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.

  Vascular health and risk management 20100101

• Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome.

  Vascular health and risk management 20100101

• Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters.

  Journal of pharmacological sciences 20100101

• Metabolic syndrome predicts vascular changes in whole body magnetic resonance imaging in patients with long standing diabetes mellitus.

  Cardiovascular diabetology 20100101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• Role of olmesartan in combination therapy in blood pressure control and vascular function.

  Vascular health and risk management 20100101

• Aliskiren and valsartan combination therapy for the management of hypertension.

  Vascular health and risk management 20100101

• Renal protection in diabetes: lessons from ONTARGET.

  Cardiovascular diabetology 20100101

• New class of agents for treatment of hypertension: focus on direct renin inhibition.

  Vascular health and risk management 20100101

• Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.

  BMC nephrology 20100101

• Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies.

  Vascular health and risk management 20100101

• Population based screening for chronic kidney disease: cost effectiveness study.

  BMJ (Clinical research ed.) 20100101

• Angiotensin-converting enzyme inhibitors will help in improving stroke outcome if given immediately after stroke.

  Annals of Indian Academy of Neurology 20100101

• Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

• Folliculocentric lichen sclerosus et atrophicus.

  Skinmed 20100101

• Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly.

  Clinical interventions in aging 20100101

• Beta blockers & left ventricular hypertrophy regression.

  Indian heart journal 20100101

• Cardio classics revisited--focus on the role of candesartan.

  Vascular health and risk management 20100101

• Dual antiplatelet therapy in secondary prevention of ischemic stroke: a ghost from the past or a new frontier?

  Stroke research and treatment 20100101

• Organic nitrates and nitrate resistance in diabetes: the role of vascular dysfunction and oxidative stress with emphasis on antioxidant properties of pentaerithrityl tetranitrate.

  Experimental diabetes research 20100101

• Comparative bioavailability of two irbesartan/hydrochlorothiazide tablet formulations in Indonesian healthy subjects.

  Arzneimittel-Forschung 20100101

• [Effect of irbesartan of the function of hemocoagulative component of hemostasis in patients with arterial hypertension during metabolic syndrome].

  Klinicheskaia meditsina 20100101

• Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?

  International journal of nephrology and renovascular disease 20100101

• Clinical and economic considerations of antiobesity treatment: a review of orlistat.

  ClinicoEconomics and outcomes research : CEOR 20100101

• Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension - update on clinical utility.

  Integrated blood pressure control 20100101

• Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination.

  Integrated blood pressure control 20100101

• Evidence-based approach for managing hypertension in type 2 diabetes.

  Integrated blood pressure control 20100101

• Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction.

  Integrated blood pressure control 20100101

• Fixed combinations in the pragmatic management of hypertension: focus on aliskiren and hydrochlorothiazide as a single pill.

  Integrated blood pressure control 20100101

• Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals.

  Integrated blood pressure control 20100101

• Impact of telmisartan in modifying vascular risk.

  Integrated blood pressure control 20100101

• Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes.

  Integrated blood pressure control 20100101

• Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control.

  Integrated blood pressure control 20100101

• Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination.

  Integrated blood pressure control 20100101

• First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination.

  Integrated blood pressure control 20100101

• Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.

  European heart journal 20091201

• Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.

  Hypertension (Dallas, Tex. : 1979) 20091201

• Optimizing antiplatelet therapy in high-risk patients with atrial fibrillation: insights from Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE A).

  Stroke 20091201

• Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats.

  Journal of hypertension 20091201

• Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT.

  European journal of heart failure 20091201

• Rational of the use of aliskiren in hypertension and beyond.

  Minerva cardioangiologica 20091201

• [Effects of irbesartan on renal advanced glycation end products and their receptor in rats with early diabetic nephropathy].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20091201

• Biochemical effects of irbesartan in experimental diabetic nephropathy.

  Indian journal of pharmacology 20091201

• Nephrotic syndrome in diabetic kidney disease: an evaluation and update of the definition.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20091101

• Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study.

  European heart journal 20091101

• Irbesartan-mediated reduction of renal and cardiac damage in insulin resistant JCR : LA-cp rats.

  British journal of pharmacology 20091101

• Hypertension and diabetes: should we treat early surrogates? What are the cons?

  Diabetes care 20091101

• Should 24-h ambulatory blood pressure monitoring be done in every patient with diabetes?

  Diabetes care 20091101

• Dual blockade of the renin-angiotensin system in diabetic nephropathy.

  Diabetes care 20091101

• Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage.

  Korean circulation journal 20091101

• Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.

  Diabetes care 20091001

• Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial.

  Diabetologia 20091001

• Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation.

  Hypertension (Dallas, Tex. : 1979) 20091001

• Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.

  Journal of the American Society of Nephrology : JASN 20091001

• Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20091001

• Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively.

  American journal of hypertension 20090901

• Studies on the effect of water-soluble polymers on drug-cyclodextrin complex solubility.

  AAPS PharmSciTech 20090901

• Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice.

  Hepatology (Baltimore, Md.) 20090901

• Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction.

  Circulation. Heart failure 20090901

• The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SILVHIA).

  Echocardiography (Mount Kisco, N.Y.) 20090801

• Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake.

  Diabetes care 20090801

• The value of irbesartan in the management of hypertension.

  Expert opinion on pharmacotherapy 20090801

• Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

  International journal of clinical practice 20090801

• The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090801

• [The I-PRESERVE study].

  Giornale italiano di cardiologia (2006) 20090801

• Matrix elimination ion chromatography method for trace level azide determination in irbesartan drug.

  Journal of chromatographic science 20090801

• Angiotensin blockade to reduce microvascular damage in diabetes mellitus.

  Deutsches Arzteblatt international 20090801

• Recent advances in pharmacotherapy of atrial fibrillation.

  Indian journal of pharmacology 20090801

• Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090701

• Angiotensin II receptor blockers in pregnancy: a report of five cases.

  Reproductive toxicology (Elmsford, N.Y.) 20090701

• Hydrophilic interaction chromatography-tandem mass spectrometric analysis of irbesartan in human plasma: application to pharmacokinetic study of irbesartan.

  Journal of separation science 20090701

• Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles.

  European heart journal 20090601

• HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies.

  Biomedical chromatography : BMC 20090601

• Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib.

  Journal of chemotherapy (Florence, Italy) 20090601

• [Comparison of amiodarone plus irbesartan regimen versus amiodarone alone on maintaining sinus rhythm in rheumatic heart disease patients with persistent atrial fibrillation post valve replacement and cardioversion].

  Zhonghua xin xue guan bing za zhi 20090601

• ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction.

  Annals of internal medicine 20090519

• [How to follow-up on the recommendations of the ESH/ESC guidelines for different kinds of blood pressure measurement methods].

  Praxis 20090513

• TANK-binding kinase 1 mediates phosphorylation of insulin receptor at serine residue 994: a potential link between inflammation and insulin resistance.

  The Journal of endocrinology 20090501

• Diabetic cardiomyopathy.

  Clinical science (London, England : 1979) 20090501

• Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.

  International journal of impotence research 20090501

• Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.

  International journal of clinical practice 20090501

• [Pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20090501

• The risks and benefits of initial irbesartan/hydrochlorothiazide combination therapy in patients with severe hypertension.

  Journal of clinical hypertension (Greenwich, Conn.) 20090501

• [Effect of ginsenoside Rgl on the expression of TNF-alpha and MCP-1 in rats with diabetic nephropathy].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20090501

• Simultaneous quantification of losartan and active metabolite in human plasma by liquid chromatography-tandem mass spectrometry using irbesartan as internal standard.

  Journal of pharmaceutical and biomedical analysis 20090405

• Calcium channel blocker-associated small bowel angioedema.

  Journal of clinical gastroenterology 20090401

• Irbesartan and hydrochlorothiazide association in the treatment of hypertension.

  Current vascular pharmacology 20090401

• Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.

  Journal of the National Medical Association 20090401

• Irbesartan for heart failure with preserved ejection fraction.

  The New England journal of medicine 20090319

• Irbesartan for heart failure with preserved ejection fraction.

  The New England journal of medicine 20090319

• Irbesartan for heart failure with preserved ejection fraction.

  The New England journal of medicine 20090319

• Irbesartan for heart failure with preserved ejection fraction.

  The New England journal of medicine 20090319

• Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial.

  Diabetes care 20090301

• Aliskiren-associated acute renal failure with hyperkalemia.

  Clinical nephrology 20090301

• Preformulation study of the inclusion complex irbesartan-beta-cyclodextrin.

  AAPS PharmSciTech 20090301

• Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090201

• Plasma brain natriuretic peptide: a biochemical marker of effective blood pressure management?

  Journal of hypertension 20090201

• Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, beta-interferon study, BACH, and ATHENA.

  European journal of heart failure 20090201

• The protective effect of the RAS inhibitor on diabetic patients with nephropathy in the context of VEGF suppression.

  Acta pharmacologica Sinica 20090201

• Efficacy and safety of two treatment combinations of hypertension in very elderly patients.

  Archives of gerontology and geriatrics 20090101

• Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090101

• High-affinity interaction of sartans with H+/peptide transporters.

  Drug metabolism and disposition: the biological fate of chemicals 20090101

• Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter.

  Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20090101

• Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats.

  Pharmacology 20090101

• Standards of medical care in diabetes--2009.

  Diabetes care 20090101

• Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways.

  PPAR research 20090101

• Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101

• [Irbasartan in patients with hart failure and preserved left-ventricular systolic function. Results of the I-PRESERVE study].

  Kardiologiia 20090101

• Genetic polymorphisms and the risk of accelerated renal function decline in women.

  PloS one 20090101

• Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.

  Cardiovascular diabetology 20090101

• Analysis of published economic evaluations of angiotensin receptor blockers.

  Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20090101

• Effects of Astragaloside IV on heart failure in rats.

  Chinese medicine 20090101

• The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies.

  Mediators of inflammation 20090101

• Candesartan cilexetil in the treatment of chronic heart failure.

  Vascular health and risk management 20090101

• Results of the ONTARGET and TRANSCEND studies: an update and discussion.

  Vascular health and risk management 20090101

• Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension.

  Vascular health and risk management 20090101

• The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man.

  Vascular health and risk management 20090101

• Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.

  Vascular health and risk management 20090101

• Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.

  Vascular health and risk management 20090101

• Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial.

  Vascular health and risk management 20090101

• Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.

  Vascular health and risk management 20090101

• Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.

  Vascular health and risk management 20090101

• Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.

  Vascular health and risk management 20090101

• Impact of statins and ACE inhibitors on mortality after COPD exacerbations.

  Respiratory research 20090101

• Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension.

  Clinical interventions in aging 20090101

• Radioligand binding assays: application of [(125)I]angiotensin II receptor binding.

  Methods in molecular biology (Clifton, N.J.) 20090101

• Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats.

  Cardiovascular diabetology 20090101

• Understanding heart failure with preserved ejection fraction: clinical importance and future outlook.

  Congestive heart failure (Greenwich, Conn.) 20090101

• Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension.

  Vascular health and risk management 20090101

• Irbesartan improves arterial compliance more than lisinopril.

  Vascular health and risk management 20090101

• Advanced glycation endproducts in sepsis and mechanical ventilation: extra or leading man?

  Critical care (London, England) 20090101

• A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention.

  Vascular health and risk management 20090101

• Restoration of podocyte structure and improvement of chronic renal disease in transgenic mice overexpressing renin.

  PloS one 20090101

• Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?

  PPAR research 20090101

• Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.

  Therapeutics and clinical risk management 20090101

• A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers.

  Therapeutics and clinical risk management 20090101

• Cardiovascular disease in patients with chronic kidney disease.

  Vascular health and risk management 20090101

• Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study.

  Vascular health and risk management 20090101

• Drugs with blocking effects on the renin-angiotensin-aldosterone system do not improve endothelial dysfunction long-term in hypertensive patients.

  The Journal of international medical research 20090101

• Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation.

  Vascular health and risk management 20090101

• Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Diabetic nephropathy.

  Diabetology & metabolic syndrome 20090101

• A rare presentation of micro-angiopathic haemolytic anaemia in a critically ill patient: a case report.

  Cases journal 20090101

• Hypokalemia induced myopathy as first manifestation of primary hyperaldosteronism - an elderly patient with unilateral adrenal hyperplasia: a case report.

  Cases journal 20090101

• Celiac disease associated membranous nephropathy - a rare cause or coincidence? A case report.

  Cases journal 20090101

• The role of urate and xanthine oxidase in vascular oxidative stress: future directions.

  Therapeutics and clinical risk management 20090101

• Irbesartan reduced heart failure in ACTIVE-I trial of patients with atrial fibrillation.

  Cardiovascular journal of Africa 20090101

• Mitigating micro-and macro-vascular complications of diabetes beginning in adolescence.

  Vascular health and risk management 20090101

• Comparative assessment of angiotensin receptor blockers in different clinical settings.

  Vascular health and risk management 20090101

• Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice.

  Vascular health and risk management 20090101

• Lanthanum associated abnormal liver function tests in two patients on dialysis: a case report.

  Journal of medical case reports 20090101

• Ion Pair-HPLC Method for the Simultaneous Estimation of Quinapril and Hydrochlorothiazide in Tablets.

  Indian journal of pharmaceutical sciences 20090101

• Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact.

  Core evidence 20090101

• Telmisartan as a peroxisome proliferator-activated receptor-γ ligand is a new target in the treatment of human renal cell carcinoma.

  Molecular medicine reports 20090101

• Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials.

  Integrated blood pressure control 20090101

• Irbesartan in patients with heart failure and preserved ejection fraction.

  The New England journal of medicine 20081204

• Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081201

• Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.

  Journal of human hypertension 20081201

• Improvement of endothelial function of the corpus cavernosum in apolipoprotein E knockout mice treated with irbesartan.

  The Journal of pharmacology and experimental therapeutics 20081201

• The effects of ACE inhibitor and angiotensin receptor blocker on clusterin and apoptosis in the kidney tissue of streptozotocin-diabetic rats.

  Journal of molecular histology 20081201

• Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium.

  European journal of heart failure 20081201

• Treatment of patients with heart failure and preserved ejection fraction.

  Current treatment options in cardiovascular medicine 20081201

• Telmisartan and carotid intima-media thickness regression: a class effect of angiotensin-receptor blockers?

  Hypertension research : official journal of the Japanese Society of Hypertension 20081201

• Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.

  Clinical therapeutics 20081201

• Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine.

  Vascular health and risk management 20081201

• Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy.

  Vascular health and risk management 20081201

• Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension.

  Vascular health and risk management 20081201

• The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target.

  Vascular health and risk management 20081201

• Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.

  Vascular health and risk management 20081201

• Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy.

  Hepatology international 20081201

• Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.

  Biologics : targets & therapy 20081201

• Angiotensin II upregulates renin-angiotensin system in human isolated T lymphocytes.

  Regulatory peptides 20081129

• [Diastolic heart failure: AT1 blocker without effect].

  MMW Fortschritte der Medizin 20081120

• Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.

  Circulation 20081111

• Predictors of cognitive decline in older individuals with diabetes.

  Diabetes care 20081101

• Expression of renin-angiotensin system and peroxisome proliferator-activated receptors in alcoholic cardiomyopathy.

  Alcoholism, clinical and experimental research 20081101

• Endothelial progenitor cells dysfunction and senescence: contribution to oxidative stress.

  Current cardiology reviews 20081101

• Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice.

  Diabetes 20081001

• Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney.

  Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20081001

• Role of angiotensin II, endothelin-1 and L-type calcium channel in the development of glomerular, tubulointerstitial and perivascular fibrosis.

  Journal of hypertension 20081001

• Clinical profile of eprosartan: a different angiotensin II receptor blocker.

  Cardiovascular & hematological agents in medicinal chemistry 20081001

• The relationship between proteinuria and coronary risk: a systematic review and meta-analysis.

  PLoS medicine 20081001

• Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes.

  Saudi medical journal 20081001

• Effects of aerobic exercise training and irbesartan on blood pressure and heart rate variability in patients with chronic obstructive pulmonary disease.

  Canadian respiratory journal 20081001

• The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.

  Vascular health and risk management 20081001

• Autonomic nervous system and cardiovascular system.

  Indian journal of pharmacology 20081001

• [Role of Rho-Rock pathways induced by angiotensin II in hepatic stellate cell contraction].

  Zhonghua yi xue za zhi 20080909

• Hallucinations and tremors due to oral therapeutic doses of erythromycin and methylprednisolone.

  Internal and emergency medicine 20080901

• Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes.

  Diabetes 20080901

• Central estrogen inhibition of angiotensin II-induced hypertension in male mice and the role of reactive oxygen species.

  American journal of physiology. Heart and circulatory physiology 20080901

• Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect.

  Pharmacoepidemiology and drug safety 20080901

• [Clinical efficacy of irbesartan and amiodarone in elderly patients with paroxysmal atrial fibrillation].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20080901

• A randomized trial of the effect of an angiotensin II receptor blocker SR47436 (irbesartan) on 24-hour blood pressure in patients with essential hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080901

• Improved dissolution of a poorly water soluble drug in solid dispersions with polymeric and non-polymeric hydrophilic additives.

  Acta pharmaceutica (Zagreb, Croatia) 20080901

• Simultaneous determination of olmesartan medoxomil and irbesartan and hydrochlorothiazide in pharmaceutical formulations and human serum using high performance liquid chromatography.

  Se pu = Chinese journal of chromatography 20080901

• Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside.

  Biologics : targets & therapy 20080901

• Diastolic dysfunction and atrial fibrillation.

  Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20080801

• Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways.

  Arteriosclerosis, thrombosis, and vascular biology 20080801

• Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease.

  European heart journal 20080801

• Telmisartan is a potent target for prevention and treatment in human prostate cancer.

  Oncology reports 20080801

• Comparison of the effects of quinapril and irbesartan on P-wave dispersion in hypertensive patients.

  Advances in therapy 20080801

• Irbesartan attenuates Ang II-induced BMP-2 expression in human umbilical vein endothelial cells.

  Vascular medicine (London, England) 20080801

• The renin-angiotensin system and diabetes: an update.

  Vascular health and risk management 20080801

• Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril.

  Vascular health and risk management 20080801

• Gender-specific regulation of pancreatic islet blood flow, insulin levels and glycaemia in spontaneously diabetic Goto-Kakizaki rats.

  Clinical science (London, England : 1979) 20080701

• Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat.

  American journal of physiology. Endocrinology and metabolism 20080701

• The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.

  American journal of hypertension 20080701

• Reduction of proteinuria with angiotensin receptor blockers.

  Nature clinical practice. Cardiovascular medicine 20080701

• The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20080701

• [Protective effects of Shenkangwan against podocyte injury in rats with early diabetic nephropathy].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080701

• Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial.

  Journal of women's health (2002) 20080701

• [Role of renin-angiotensin system, PPARalpha, PPARgamma in the development of alcoholic cardiomyopathy].

  Zhonghua xin xue guan bing za zhi 20080701

• Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.

  The New England journal of medicine 20080626

• Direct renin inhibition: clinical pharmacology.

  Journal of molecular medicine (Berlin, Germany) 20080601

• Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study).

  Clinical nephrology 20080601

• [Angiotensin II stimulates platelet-derived growth factor-B expression in hepatic stellate cells by activating EGR-1].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080601

• [Effect of angiotensin II on Rho-Rock pathway in rat hepatic stellate cell contraction].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080601

• Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20080601

• Ask the doctor. My blood pressure is high when I first get up in the morning, generally around 150/80, but always drops back to normal (around 120/60) by 9 a.m. and stays that way throughout the day. I take 150 milligrams of Avapro in the morning and again in the evening, along with a diuretic in the morning. I check my blood pressure at home using a meter that was verified in my cardiologist's office. My doctor says I shouldn't worry about the temporary high morning blood pressure. What do you think?

  Harvard heart letter : from Harvard Medical School 20080601

• The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis?

  Vascular health and risk management 20080601

• Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination.

  Vascular health and risk management 20080601

• Onset and enhancement of systemic sclerosis after treatments for multiple sclerosis.

  Rheumatology international 20080501

• The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction.

  Heart (British Cardiac Society) 20080501

• Integrative control of coronary resistance vessel tone by endothelin and angiotensin II is altered in swine with a recent myocardial infarction.

  American journal of physiology. Heart and circulatory physiology 20080501

• Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).

  Stroke 20080501

• Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk.

  International journal of clinical practice 20080501

• Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.

  Hypertension (Dallas, Tex. : 1979) 20080501

• Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?

  Journal of hypertension 20080501

• Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study.

  The American journal of gastroenterology 20080501

• Treating Hispanic patients for type 2 diabetes mellitus: special considerations.

  The Journal of the American Osteopathic Association 20080501

• Renin-angiotensin-aldosterone system gene polymorphisms and antihypertensive response to irbesartan in Chinese hypertensives.

  Methods and findings in experimental and clinical pharmacology 20080501

• A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.

  Journal of human hypertension 20080401

• ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.

  Obesity (Silver Spring, Md.) 20080401

• Renin inhibition with aliskiren.

  Clinical and experimental pharmacology & physiology 20080401

• A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080401

• Aliskiren: new drug. Arterial hypertension: no evidence of clinical efficacy.

  Prescrire international 20080401

• Early detection and management of the high-risk patient with elevated blood pressure.

  Vascular health and risk management 20080401

• Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure.

  International journal of cardiology 20080328

• Functional coupling of angiotensin II type 1 receptor with insulin resistance of energy substrate uptakes in immortalized cardiomyocytes (HL-1 cells).

  British journal of pharmacology 20080301

• Penile angioedema associated with the use of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080301

• Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker.

  European journal of endocrinology 20080301

• Effects of angiotensin II type 1-receptor blockade on retinal endothelial function.

  Journal of hypertension 20080301

• Separation and quantitation of several angiotensin II receptor antagonist drugs in human urine by a SPE-HPLC-DAD method.

  Journal of separation science 20080301

• Beneficial effect of angiotensin II type 1 receptor blocker antihypertensive treatment on arterial stiffness: the role of smoking.

  Journal of clinical hypertension (Greenwich, Conn.) 20080301

• Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20080301

• Effects of irbesartan and perindopril on forearm reactive hyperemia and inflammatory process, in normotensive patients with coronary artery disease.

  International journal of cardiology 20080220

• Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression.

  Circulation 20080212

• Hypothalamic angiotensinergic-noradrenergic systems interaction in fructose induced hypertension.

  Regulatory peptides 20080207

• Gene expression pattern in biomechanically stretched cardiomyocytes: evidence for a stretch-specific gene program.

  Hypertension (Dallas, Tex. : 1979) 20080201

• Prolonged QT interval, syncope, and delirium with galantamine.

  The Annals of pharmacotherapy 20080201

• Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.

  Current medical research and opinion 20080201

• Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.

  European journal of clinical pharmacology 20080201

• Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial.

  European journal of heart failure 20080201

• Endothelial effects of antihypertensive treatment: focus on irbesartan.

  Vascular health and risk management 20080201

• Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention.

  Vascular health and risk management 20080201

• An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20080101

• Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.

  Journal of the American Society of Nephrology : JASN 20080101

• Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial.

  American heart journal 20080101

• Up-regulation of PPARgamma in myocardial infarction.

  European journal of heart failure 20080101

• Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy.

  The American journal of geriatric cardiology 20080101

• Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study.

  Journal of clinical hypertension (Greenwich, Conn.) 20080101

• Combination of hormone therapy with sartan: an option for hypertensive postmenopausal women?

  Menopause (New York, N.Y.) 20080101

• Effects of estradiol and the angiotensin II receptor blocker irbesartan on vascular function in postmenopausal women.

  Menopause (New York, N.Y.) 20080101

• Alterations in vasomotor control of coronary resistance vessels in remodelled myocardium of swine with a recent myocardial infarction.

  Medical & biological engineering & computing 20080101

• [Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101

• Aliskiren: renin inhibitor for hypertension management.

  Clinical therapeutics 20080101

• [Experimental study in renal protective effect of tranilast on rats with adriamycin nephropathy].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20080101

• Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.

  Clinical pharmacokinetics 20080101

• Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.

  Nephron. Clinical practice 20080101

• Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).

  Cardiovascular diabetology 20080101

• [spACE, the last frontier? Renin inhibition in hypertension].

  Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20080101

• PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies.

  PPAR research 20080101

• Irbesartan/Hydrochlorothiazide : in moderate to severe hypertension.

  Drugs 20080101

• Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome.

  International journal of impotence research 20080101

• Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.

  Scandinavian journal of clinical and laboratory investigation 20080101

• Irbesartan: a review of its use in hypertension and diabetic nephropathy.

  Drugs 20080101

• Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxidative stress and adhesion molecules in patients with persistent atrial fibrillation.

  Clinical drug investigation 20080101

• Family physician and endocrinologist coordination as the basis for diabetes care in clinical practice.

  BMC endocrine disorders 20080101

• Identification and control of a degradation product in Avapro film-coated tablet: low dose formulation.

  Pharmaceutical development and technology 20080101

• The prince and the pauper. A tale of anticancer targeted agents.

  Molecular cancer 20080101

• Are decision trees a feasible knowledge representation to guide extraction of critical information from randomized controlled trial reports?

  BMC medical informatics and decision making 20080101

• Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care.

  BMC cardiovascular disorders 20080101

• Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model.

  Journal of gastroenterology 20080101

• Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.

  Renal failure 20080101

• [Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus].

  Kardiologiia 20080101

• Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy.

  Cardiovascular journal of Africa 20080101

• Association of alpha1a-adrenergic receptor polymorphism and blood pressure phenotypes in the Brazilian population.

  BMC cardiovascular disorders 20080101

• Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data.

  European journal of drug metabolism and pharmacokinetics 20080101

• Abstracts of papers presented at the 2008 pittsburgh conference.

  Journal of automated methods & management in chemistry 20080101

• Slowing the progression of kidney disease in patients with diabetes.

  Journal of the American Society of Hypertension : JASH 20080101

• Molecular mechanism of edema formation in nephrotic syndrome: therapeutic implications.

  Pediatric nephrology (Berlin, Germany) 20071201

• Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study.

  Journal of human hypertension 20071201

• Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide.

  International journal of clinical practice 20071201

• Synthesis and screening for acetylcholinesterase inhibitor activity of some novel 2-butyl-1,3-diaza-spiro[4,4]non-1-en-4-ones: derivatives of irbesartan key intermediate.

  Bioorganic & medicinal chemistry 20071201

• Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring.

  European journal of clinical pharmacology 20071201

• A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20071201

• Validated quantitation of angiotensin II receptor antagonists (ARA-II) in human plasma by liquid-chromatography-tandem mass spectrometry using minimum sample clean-up and investigation of ion suppression.

  Therapeutic drug monitoring 20071201

• Initial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy.

  Journal of clinical hypertension (Greenwich, Conn.) 20071201

• The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk.

  Journal of clinical hypertension (Greenwich, Conn.) 20071201

• Aliskiren--an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension.

  Vascular health and risk management 20071201

• Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications.

  Vascular health and risk management 20071201

• Clinical trial update: focus on the ONTARGET study.

  Vascular health and risk management 20071201

• Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature.

  Vascular health and risk management 20071201

• Reduction of C-reactive protein and the use of anti-hypertensives.

  Vascular health and risk management 20071201

• Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.

  Journal of the American College of Cardiology 20071127

• Influence of irbesartan on expression of ILK and its relationship with epithelial-mesenchymal transition in mice with unilateral ureteral obstruction.

  Acta pharmacologica Sinica 20071101

• [Long-term follow-up of cardiovascular risk markers in patients with hypertension. Rationale, design, and baseline characteristics of the i-Search Plus Registry].

  Medizinische Klinik (Munich, Germany : 1983) 20071015

• [Albuminuria: an indicator of cardiovascular risk].

  Medizinische Klinik (Munich, Germany : 1983) 20071015

• Development of a solid phase extraction procedure for HPLC-DAD determination of several angiotensin II receptor antagonists in human urine using mixture design.

  Talanta 20071015

• AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease.

  Atherosclerosis 20071001

• Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.

  Kidney international 20071001

• Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.

  International journal of clinical practice 20071001

• Albuminuria reduction: the holy grail for kidney protection.

  Kidney international 20071001

• Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension.

  Journal of clinical hypertension (Greenwich, Conn.) 20071001

• Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: effectiveness in combination with diuretics or beta-blockers for treating hypertension.

  Vascular health and risk management 20071001

• Determination of hydrochlorothiazide in human plasma by liquid chromatography/tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20070903

• Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.

  Atherosclerosis 20070901

• Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension.

  International journal of clinical practice 20070901

• A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20070901

• [Is the serum concentration of pentosidine a predictor of cardiovascular events in patients with type 2 diabetes and kidney disease?].

  Deutsche medizinische Wochenschrift (1946) 20070901

• Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).

  Journal of hypertension 20070901

• [Observation on therapeutic effects of combined acupuncture and medicine therapy and simple medication on renal hypertension of chronic kidney disease].

  Zhongguo zhen jiu = Chinese acupuncture & moxibustion 20070901

• Pulmonary hypertension and chronic cor pulmonale in COPD.

  International journal of chronic obstructive pulmonary disease 20070901

• Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury.

  The American journal of pathology 20070801

• [Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].

  Der Internist 20070801

• Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.

  American journal of hypertension 20070801

• [Expression of cardiotrophin-1 and effects of irbesartan in adriamycin induced cardiomyopathy in rats].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20070801

• [Short- and long-term therapeutic effects of combination therapy with perindopril and irbesartan in a rat model of dilated cardiomyopathy].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20070801

• Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes.

  Drug metabolism and pharmacokinetics 20070801

• Arterial stiffness and pharmacological interventions--the TRanscend arterial stiffNess Substudy (TRANS study).

  Vascular health and risk management 20070801

• Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination.

  Vascular health and risk management 20070801

• Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors.

  Vascular health and risk management 20070801

• Importance of intracellular angiotensin II in vascular smooth muscle cell apoptosis: inhibition by the angiotensin AT1 receptor antagonist irbesartan.

  European journal of pharmacology 20070719

• Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice.

  Cardiovascular research 20070701

• Diagnosis of primary aldosteronism in a patient with an incidentally found adrenal mass.

  Nature clinical practice. Endocrinology & metabolism 20070701

• Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.

  Clinical therapeutics 20070701

• Hypophagic effect of the angiotensin AT1 receptor antagonist irbesartan in rats.

  European journal of pharmacology 20070614

• Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis.

  The European journal of health economics : HEPAC : health economics in prevention and care 20070601

• Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.

  Journal of clinical pharmacy and therapeutics 20070601

• [Experiment research on preventive effect of matrine on rat chronic nephrotoxicity induced by cyclosporin A].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20070601

• Manidipine-delapril combination in the management of hypertension.

  Vascular health and risk management 20070601

• Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?

  Vascular health and risk management 20070601

• Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.

  Vascular health and risk management 20070601

• Simultaneous determination of 6 beta-blockers, 3 calcium-channel antagonists, 4 angiotensin-II antagonists and 1 antiarrhythmic drug in post-mortem whole blood by automated solid phase extraction and liquid chromatography mass spectrometry. Method development and robustness testing by experimental design.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• Severe anemia caused by the angiotensin receptor blocker irbesartan after renal transplantation.

  Pediatric nephrology (Berlin, Germany) 20070501

• Palatability of angiotensin II antagonists among nephropathic children.

  British journal of clinical pharmacology 20070501

• Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.

  Hypertension (Dallas, Tex. : 1979) 20070501

• Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.

  Journal of internal medicine 20070501

• Extractive-spectrophotometric determination of disopyramide and irbesartan in their pharmaceutical formulation.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20070401

• Liquid chromatographic determination of irbesartan in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401

• Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?

  Current opinion in pharmacology 20070401

• Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases.

  Journal of gastroenterology and hepatology 20070401

• Angiotensin II receptor blockers for the treatment of heart failure: a class effect?

  Pharmacotherapy 20070401

• Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.

  Fundamental & clinical pharmacology 20070401

• [Effects of irbesartan on left ventricular diasolic function and heart rate variability of patients with acute myocardial infarction].

  Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue 20070401

• [Efficiency of rituximab treatment for recurrence of membranous glomerulopathy after renal transplantation].

  Nephrologie & therapeutique 20070401

• [Effects of angiotensin II receptor antagonist on rat podocyte injury in early diabetic nephropathy].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20070401

• Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.

  Clinical therapeutics 20070401

• ANG II type 1 receptor antagonist irbesartan inhibits coronary angiogenesis stimulated by chronic intermittent hypoxia in neonatal rats.

  American journal of physiology. Heart and circulatory physiology 20070301

• Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism.

  Diabetes 20070301

• Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage.

  Expert review of cardiovascular therapy 20070301

• Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation.

  The Annals of pharmacotherapy 20070301

• Neuropsychiatric consequences of cardiovascular medications.

  Dialogues in clinical neuroscience 20070301

• Role of TGF-beta1 in vascular smooth muscle cell apoptosis induced by angiotensin II.

  European journal of pharmacology 20070205

• Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

  Hypertension (Dallas, Tex. : 1979) 20070201

• The effects of the angiotensin II receptor (type I) antagonist irbesartan in patients with cardiac syndrome X.

  Heart (British Cardiac Society) 20070201

• Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme.

  Vascular health and risk management 20070201

• Trandolapril/verapamil combination in hypertensive diabetic patients.

  Vascular health and risk management 20070201

• Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy.

  Vascular health and risk management 20070201

• Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials.

  Vascular health and risk management 20070201

• Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat.

  Regulatory peptides 20070110

• Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats.

  Clinical science (London, England : 1979) 20070101

• Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects.

  Journal of clinical pharmacology 20070101

• Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects.

  PPAR research 20070101

• Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.

  Cardiovascular diabetology 20070101

• Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature.

  Hypertension in pregnancy 20070101

• The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats.

  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20070101

• Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis.

  BMC nephrology 20070101

• Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.

  Clinical pharmacokinetics 20070101

• Metabolic syndrome: treatment of hypertensive patients.

  American journal of therapeutics 20070101

• Aliskiren: a review of its use in the management of hypertension.

  Drugs 20070101

• Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.

  Cardiology in review 20070101

• Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.

  Cardiovascular diabetology 20070101

• Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure.

  Clinical drug investigation 20070101

• BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.

  Clinical drug investigation 20070101

• Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study.

  Cardiovascular diabetology 20070101

• Aliskiren: an oral renin inhibitor for the treatment of hypertension.

  Cardiology in review 20070101

• Perindopril: the evidence of its therapeutic impact in hypertension.

  Core evidence 20070101

• Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.

  Diabetes 20061201

• Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.

  Journal of clinical hypertension (Greenwich, Conn.) 20061201

• The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients.

  Journal of endocrinological investigation 20061201

• Olmesartan medoxomil: current status of its use in monotherapy.

  Vascular health and risk management 20061201

• Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension.

  Vascular health and risk management 20061201

• [Treatment of hypertension can do more. Using chances for organ protection].

  MMW Fortschritte der Medizin 20061109

• [Successful high dosage fixed combination. 7 of 10 patients achieve target blood pressure].

  MMW Fortschritte der Medizin 20061109

• Coronary vasoconstrictor influence of angiotensin II is reduced in remodeled myocardium after myocardial infarction.

  American journal of physiology. Heart and circulatory physiology 20061101

• A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

  Current medical research and opinion 20061101

• Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.

  Hypertension research : official journal of the Japanese Society of Hypertension 20061101

• Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.

  Pediatric nephrology (Berlin, Germany) 20061001

• Irbesartan attenuates contrast media-induced NRK-52E cells apoptosis.

  Pharmacological research 20061001

• Involvement of drug-specific T cells in acute drug-induced interstitial nephritis.

  Journal of the American Society of Nephrology : JASN 20061001

• The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20061001

• Optimising stroke prevention in non-valvular atrial fibrillation.

  Expert opinion on pharmacotherapy 20061001

• Recent insights into the role of prostanoids in atherosclerotic vascular disease.

  Current vascular pharmacology 20061001

• [The effects of angiotensin II receptor blockers in hypertensive patients complicating hyperuricaemia].

  Zhonghua xin xue guan bing za zhi 20061001

• [Inhibitory effect of irbesartan on restenosis after balloon angioplasty and mechanism thereof: experiment with rabbits].

  Zhonghua yi xue za zhi 20060912

• Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial.

  Journal of human hypertension 20060901

• Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.

  Vascular pharmacology 20060901

• Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation.

  European heart journal 20060901

• Inhibition of angiotensin II type 1 receptors reduces atrial stunning and spontaneous echo contrast after electrical cardioversion of atrial fibrillation.

  European heart journal 20060901

• Gender differences in the renal response to renin-angiotensin system blockade.

  Journal of the American Society of Nephrology : JASN 20060901

• Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.

  Journal of hypertension 20060901

• Proposed new score to rate the strength of evidence and its application to large-scale clinical trials of angiotensin-receptor blockers.

  Circulation journal : official journal of the Japanese Circulation Society 20060901

• Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).

  American journal of hypertension 20060901

• Treatment of diastolic dysfunction in hypertensive left ventricular hypertrophy.

  American journal of hypertension 20060901

• [Effects of irbesartan on nitric oxide system in the heart of diabetic rats].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20060901

• Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs.

  European journal of pharmacology 20060814

• [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].

  Deutsche medizinische Wochenschrift (1946) 20060804

• Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats.

  Journal of hypertension 20060801

• Systemic illness with skin eruption, fever and positive lymphocyte transformation test in a patient on irbesartan.

  The British journal of dermatology 20060801

• AT2 receptor stimulation may halt progression of pheochromocytoma.

  Annals of the New York Academy of Sciences 20060801

• Pancreatic islet blood flow is selectively enhanced by captopril, irbesartan and pravastatin, and suppressed by palmitate.

  Biochemical and biophysical research communications 20060721

• Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathy.

  Circulation 20060718

• Hypothalamic cardiovascular effects of angiotensin-(1-7) in spontaneously hypertensive rats.

  Regulatory peptides 20060715

• Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress: the EPAS trial.

  Circulation 20060704

• Carvedilol-induced antagonism of angiotensin II: a matter of alpha1-adrenoceptor blockade.

  Journal of hypertension 20060701

• Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.

  Journal of clinical hypertension (Greenwich, Conn.) 20060701

• [Renin-angiotensin system].

  Nihon rinsho. Japanese journal of clinical medicine 20060701

• [PPARgamma-activating properties of angiotensin receptor blockers].

  Nihon rinsho. Japanese journal of clinical medicine 20060701

• [Effect of combination of Chinese and Western medicines on sinus rhythm maintenance in patients with auricular fibrillation after conversion].

  Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20060701

• [Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].

  MMW Fortschritte der Medizin 20060622

• Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.

  Lancet (London, England) 20060610

• Lichenoid drug eruption due to an antihypertonic drug containing irbesartan and hydrochlorothiazide.

  Allergy 20060601

• AT2 receptor-mediated vasodilation in the mouse heart depends on AT1A receptor activation.

  British journal of pharmacology 20060601

• Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis.

  The American journal of pathology 20060601

• Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.

  American heart journal 20060601

• Sinus arrest and moderate hyperkalemia.

  Annales de cardiologie et d'angeiologie 20060601

• Efficacy of irbesartan on left ventricular mass and arterial stiffness in hypertensive patients.

  The Korean journal of internal medicine 20060601

• Valsartan in the treatment of heart attack survivors.

  Vascular health and risk management 20060601

• Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.

  Swiss medical weekly 20060527

• MultiSimplex and experimental design as chemometric tools to optimize a SPE-HPLC-UV method for the determination of eprosartan in human plasma samples.

  Talanta 20060515

• Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial.

  The European respiratory journal 20060501

• Quantitative analysis of irbesartan in commercial dosage forms by kinetic spectrophotometry.

  Chemical & pharmaceutical bulletin 20060501

• Angiotensin receptor blockers: new considerations in their mechanism of action.

  Journal of clinical hypertension (Greenwich, Conn.) 20060501

• Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.

  Expert review of cardiovascular therapy 20060501

• What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?

  Nature clinical practice. Nephrology 20060501

• [Effect of irbesartan on focal cerebral ischemia in rats].

  Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 20060501

• Effects of angiotensin converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats.

  Chinese medical journal 20060420

• Novel and expeditious microwave-assisted three-component reactions for the synthesis of spiroimidazolin-4-ones.

  The Journal of organic chemistry 20060414

• Influence of angiotensin II receptors blocking on overall left ventricle's performance of patients with acute myocardial infarction of limited extent. Echocardiographic assessment.

  The international journal of cardiovascular imaging 20060401

• Terlipressin for refractory hypotension following angiotensin-II receptor antagonist overdose.

  Anaesthesia 20060401

• Economic evaluation of angiotensin receptor blockers in type 2 diabetes, hypertension, and nephropathy.

  Journal of the American Society of Nephrology : JASN 20060401

• Use of antihypertension agents for the suppression of arterial pulse pressure waveforms in patients with intracranial aneurysms.

  Journal of neurosurgery 20060401

• Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.

  Journal of the National Medical Association 20060401

• Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.

  Arquivos brasileiros de endocrinologia e metabologia 20060401

• Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats.

  European journal of pharmacology 20060318

• [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].

  Praxis 20060315

• Targeting effective blood pressure control with angiotensin receptor blockers.

  International journal of clinical practice 20060301

• Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca2+-ATPase activity in rat cardiac pressure-overload hypertrophy.

  Journal of Zhejiang University. Science. B 20060301

• Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20060301

• Effects of eprosartan on target organ protection.

  Vascular health and risk management 20060301

• Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.

  Clinical journal of the American Society of Nephrology : CJASN 20060301

• Role of angiotensin II receptor blockers in atherosclerotic plaque stability.

  Expert opinion on pharmacotherapy 20060201

• Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes.

  Diabetes & metabolism 20060201

• Novel polymer monolith microextraction using a poly(methacrylic acid-ethylene glycol dimethacrylate) monolith and its application to simultaneous analysis of several angiotensin II receptor antagonists in human urine by capillary zone electrophoresis.

  Journal of chromatography. A 20060113

• Influences of AT1 receptor blockade on tissue metabolism in obese men.

  American journal of physiology. Regulatory, integrative and comparative physiology 20060101

• Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.

  Journal of human hypertension 20060101

• Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.

  The international journal of biochemistry & cell biology 20060101

• Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.

  Journal of hypertension 20060101

• Connective tissue growth factor-mediated angiotensin II-induced hypertrophy of proximal tubular cells.

  Nephron. Experimental nephrology 20060101

• Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy.

  Current medical research and opinion 20060101

• Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b.

  Theoretical biology & medical modelling 20060101

• Angiotensin II does not affect endothelial tone in Type 1 diabetes-results of a double-blind placebo controlled trial.

  Diabetic medicine : a journal of the British Diabetic Association 20060101

• Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.

  Clinical pharmacology and therapeutics 20060101

• Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial.

  Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20060101

• CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients.

  Methods and findings in experimental and clinical pharmacology 20060101

• Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232].

  Trials 20060101

• Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall.

  BMC health services research 20060101

• A critical review of mathematical models and data used in diabetology.

  Biomedical engineering online 20060101

• Effects of blocking the renin-angiotensin system on expression and translocation of protein kinase C isoforms in the kidney of diabetic rats.

  Nephron. Experimental nephrology 20060101

• C-reactive protein (CRP)-lowering agents.

  Cardiovascular drug reviews 20060101

• Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation: the ACTIVE W trial.

  The American journal of geriatric cardiology 20060101

• ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study.

  Journal of nephrology 20060101

• Management of high-risk patients with hypertension and left ventricular hypertrophy in Germany: differences between cardiac specialists in the inpatient and outpatient setting.

  BMC public health 20060101

• [Angiotensin receptor blockers and cardiac rhythm disorders].

  Archives des maladies du coeur et des vaisseaux 20060101

• A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.

  PloS one 20060101

• PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions.

  European journal of drug metabolism and pharmacokinetics 20060101

• Polymorphism of the ACE Gene in dialysis patients: overexpression of DD genotype in type 2 diabetic end-stage renal failure patients.

  Yonsei medical journal 20051231

• Effects of losartan and irbesartan administration on brain angiotensinogen mRNA levels.

  European journal of pharmacology 20051228

• Biocompatible in-tube solid-phase microextraction coupled to HPLC for the determination of angiotensin II receptor antagonists in human plasma and urine.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20051215

• Preserving cardiac function in the hypertensive patient: why renal parameters hold the key.

  European heart journal 20051201

• Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence.

  Journal of human hypertension 20051201

• Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.

  Diabetes 20051201

• Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive dogs.

  Journal of cardiovascular pharmacology 20051201

• Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG(mREN2)27 rats.

  Metabolism: clinical and experimental 20051201

• Teratogenicity with angiotensin II receptor antagonists in pregnancy.

  Journal of endocrinological investigation 20051201

• Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers?

  Vascular health and risk management 20051201

• Patterns of antihypertensive therapy in new users of angiotensin II-receptor blockers.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20051115

• Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy.

  Journal of the American Society of Nephrology : JASN 20051101

• Up-regulation of glomerular COX-2 by angiotensin II: role of reactive oxygen species.

  Kidney international 20051101

• A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.

  American journal of hypertension 20051101

• Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats.

  Obesity research 20051101

• Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension.

  Clinical therapeutics 20051101

• [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].

  MMW Fortschritte der Medizin 20051006

• Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20051001

• CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population.

  European journal of clinical pharmacology 20051001

• Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.

  Journal of the American Society of Nephrology : JASN 20051001

• Peripheral sympatholytic actions of four AT1 antagonists: are they relevant for long-term antihypertensive efficacy?

  Journal of hypertension 20051001

• Antihypertensive, antiproteinuric therapy and myocardial infarction and stroke prevention.

  Current hypertension reports 20051001

• Acute pancreatitis associated with irbesartan therapy.

  Pancreas 20051001

• Hypotensive shock and angio-oedema from angiotensin II receptor blocker: a class effect in spite of tripled tryptase values.

  Journal of internal medicine 20051001

• The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.

  Journal of clinical hypertension (Greenwich, Conn.) 20051001

• The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.

  Journal of cardiac failure 20051001

• Failure of angiotensin II to suppress plasma renin activity in normotensive subjects with a positive family history of hypertension.

  Clinical science (London, England : 1979) 20050901

• Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.

  Kidney international 20050901

• [Experimental study of effect of carvedilol on myocardial collagen network remodeling after acute myocardial infarction in rats].

  Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue 20050901

• Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects.

  Clinical pharmacology and therapeutics 20050901

• [Clinical observation on treatment of IgA nephropathy with Huobahuagen Tablets and irbesartan].

  Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine 20050901

• Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.

  Clinical nephrology 20050901

• Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.

  Current medical research and opinion 20050901

• Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20050901

• Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis.

  Vascular health and risk management 20050901

• Antihypertensive effect of Lepidium sativum L. in spontaneously hypertensive rats.

  Journal of ethnopharmacology 20050822

• [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].

  MMW Fortschritte der Medizin 20050804

• Determination of hydrochlorothiazide and irbesartan in pharmaceuticals by fourth-order UV derivative spectrophotometry.

  Farmaco (Societa chimica italiana : 1989) 20050801

• C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy.

  Kidney international 20050801

• An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.

  Expert opinion on pharmacotherapy 20050801

• Systematic review on urine albumin testing for early detection of diabetic complications.

  Health technology assessment (Winchester, England) 20050801

• [Effects of angiotensin receptor blocker and angiotensin-coverting enzyme inhibitor on vascular endothelial function in type 2 diabetic patients with atherosclerosis: a comparative study].

  Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA 20050801

• Blockade of angiotensin II type 1 receptor diminishes cardiac hypertrophy, but does not abolish thyroxin-induced preconditioning.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20050801

• AT1 receptor blockade prevents cardiac dysfunction after myocardial infarction in rats.

  Cardiovascular drugs and therapy 20050801

• Modulation of the (Na(+)+K+)ATPase activity by Angiotensin-(1-7) in MDCK cells.

  Regulatory peptides 20050715

• Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.

  Journal of the American Society of Nephrology : JASN 20050701

• PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.

  Hypertension (Dallas, Tex. : 1979) 20050701

• Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.

  Cardiovascular research 20050701

• Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy.

  Diabetes care 20050701

• Effect of irbesartan monotherapy compared with ACE inhibitors and calcium-channel blockers on patient compliance in essential hypertension patients: a multicenter, open-labeled, three-armed study.

  Blood pressure. Supplement 20050701

• [The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension].

  Zhonghua xin xue guan bing za zhi 20050701

• Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.

  Journal of medicinal chemistry 20050630

• Effects of irbesartan on the expression of matrix metalloproteinase-2/tissue inhibitor of metalloproteinase-2 in streptozotocin-induced diabetic rat kidney.

  Chinese medical journal 20050620

• Association of osteoprotegerin with human abdominal aortic aneurysm progression.

  Circulation 20050614

• Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects.

  Journal of human hypertension 20050601

• Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050601

• Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension.

  Journal of cardiovascular pharmacology 20050601

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• A review of studies of adherence with antihypertensive drugs using prescription databases.

  Therapeutics and clinical risk management 20050601

• [Good blood pressure control even in overweight patients].

  MMW Fortschritte der Medizin 20050526

• Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.

  Circulation 20050517

• Fraxinus excelsior L. evokes a hypotensive action in normal and spontaneously hypertensive rats.

  Journal of ethnopharmacology 20050513

• Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina.

  Heart (British Cardiac Society) 20050501

• Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure.

  American heart journal 20050501

• Effect of electrolytes on the partition coefficient of irbesartan.

  Die Pharmazie 20050501

• [Effects of combination therapy with angiotensin I-converting enzyme inhibitor and angiotensin 1 receptor antagonist on ventricular remodeling and expression of endothelial nitric oxide synthase].

  Zhonghua yi xue za zhi 20050420

• Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050401

• Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists.

  Hypertension (Dallas, Tex. : 1979) 20050401

• Association of cigarette smoking with steady-state plasma concentration of irbesartan in male Chinese with hypertension.

  Methods and findings in experimental and clinical pharmacology 20050401

• [Remodelling in atrial fibrillation].

  Archives des maladies du coeur et des vaisseaux 20050401

• Conversion from migraine without aura to typical aura without headache after irbesartan.

  The journal of headache and pain 20050401

• Hypothalamic antihypertensive effect of irbesartan in chronic aortic coarctated rats.

  Pharmacology 20050301

• Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy.

  Journal of hypertension 20050301

• Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.

  Circulation 20050301

• Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization.

  Trends in pharmacological sciences 20050301

• [The renoprotect effect of shenhua recipe on 5/6 renal ablation rats].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20050301

• Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?

  Current opinion in investigational drugs (London, England : 2000) 20050301

• Clinical observation of irbesartan in treatment of vasovagal syncope.

  Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 20050301

• Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.

  Journal of the American Society of Nephrology : JASN 20050301

• Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy?

  Journal of the American Society of Nephrology : JASN 20050301

• [Therapeutic interchange standardization for antiotensin II receptor antagonists in the treatment of hypertension in the hospital setting].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20050301

• [Effects of angiotensin II and aldosterone on NF-kappaB binding activity in hepatic stellate cells].

  Zhonghua yi xue za zhi 20050216

• Effects of irbesartan on atrial cell electrophysiology.

  Chinese medical journal 20050205

• Enhanced angiotensin II-mediated effects in fibroblasts of patients with familial hypercholesterolemia.

  Journal of hypertension 20050201

• Drug-induced lithium intoxication: a case report.

  Journal of the American Geriatrics Society 20050201

• Could irbesartan trigger autoimmune cholestatic hepatitis?

  European journal of gastroenterology & hepatology 20050201

• Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20050201

• Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals.

  American journal of hypertension 20050201

• [Therapeutic implications of ACE-gene polymorphism].

  Wiener medizinische Wochenschrift (1946) 20050201

• Redefining efficacy of antihypertensive therapies beyond blood pressure reduction--the role of angiotensin II antagonists.

  International journal of clinical practice 20050201

• Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study.

  Circulation 20050125

• Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics.

  Journal of medicinal chemistry 20050113

• Examination of 209 drugs for inhibition of cytochrome P450 2C8.

  Journal of clinical pharmacology 20050101

• Microalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartan.

  Kidney international. Supplement 20050101

• AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II.

  Kidney international. Supplement 20050101

• Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.

  Kidney international. Supplement 20050101

• Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101

• Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation.

  BMC cardiovascular disorders 20050101

• A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101

• Effect of high glucose on superoxide in human mesangial cells: role of angiotensin II.

  Nephron. Experimental nephrology 20050101

• Pharmacologic treatment of chronic pediatric hypertension.

  Paediatric drugs 20050101

• [Effect of long-term therapy with contemporary drugs on diastolic cardiac function in patients with chronic heart failure].

  Kardiologiia 20050101

• Diastolic dysfunction and diastolic heart failure: diagnostic, prognostic and therapeutic aspects.

  Cardiovascular ultrasound 20050101

• Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101

• Kidney disease as CVD risk factor: implications for therapy.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20050101

• Control of hypertension with captopril affords better renal protection as compared with irbesartan in salt-loaded uremic rats.

  Nephron. Physiology 20050101

• Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey.

  BMC cardiovascular disorders 20050101

• Progression of kidney disease in type 2 diabetes - beyond blood pressure control: an observational study.

  BMC nephrology 20050101

• Pharmacokinetic and pharmacodynamic of irbesartan in renal hypertensive dogs under non-steady-state and steady-state conditions.

  European journal of drug metabolism and pharmacokinetics 20050101

• Do angiotensin II antagonists provide benefits beyond blood pressure reduction?

  Advances in therapy 20050101

• [Irbesartan induced acute hepatitis: one case].

  Gastroenterologie clinique et biologique 20050101

• Pharmacological modulation of plaque instability.

  Lupus 20050101

• Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension.

  The Journal of international medical research 20050101

• [Effect of irbesartan in proteinuric non-diabetic renal disease].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20050101

• Dose-related efficacy of irbesartan in patients, with mild-to-moderate essential hypertension.

  Therapie 20050101

• Antihypertensive effect of irbesartan and predictors of response in obesity-associated hypertension : a prospective, open-label study.

  Clinical drug investigation 20050101

• Aliskiren in hypertension: evidence for its potential therapeutic value.

  Core evidence 20050101

• Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment.

  Journal of hypertension 20041201

• Kinetics of decomposition of irbesartan in aqueous solutions determined by high performance liquid chromatography.

  Die Pharmazie 20041201

• [New insights on the molecular mechanisms of type-1 angiotensin II receptor blockers and their contribution to atherosclerotic plaque stabilization].

  Recenti progressi in medicina 20041201

• Diabetic nephropathy.

  Clinical evidence 20041201

• Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice.

  Circulation 20041109

• Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria.

  Kidney international. Supplement 20041101

• Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.

  Kidney international. Supplement 20041101

• Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial.

  Kidney international. Supplement 20041101

• Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study.

  Atherosclerosis 20041101

• Telmisartan - killing two birds with one stone.

  Expert opinion on pharmacotherapy 20041101

• Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus.

  Journal of human hypertension 20041001

• An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.

  Journal of human hypertension 20041001

• The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.

  The Annals of pharmacotherapy 20041001

• The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care.

  Current medical research and opinion 20041001

• [Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20041001

• Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies.

  Journal of clinical hypertension (Greenwich, Conn.) 20041001

• Quantitation of poloxamers in pharmaceutical formulations using size exclusion chromatography and colorimetric methods.

  Journal of pharmaceutical and biomedical analysis 20040903

• Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells.

  Journal of hypertension 20040901

• Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients.

  Diabetologia 20040901

• Pharmacoeconomic challenges in the management of diabetic nephropathy.

  Journal of managed care pharmacy : JMCP 20040901

• Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.

  Journal of managed care pharmacy : JMCP 20040901

• Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20040901

• BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20040901

• How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20040901

• Amelioration of cyclosporine nephrotoxicity by irbesartan, A selective AT1 receptor antagonist.

  Renal failure 20040901

• [Test for microalbuminuria. Life saving for hypertensive and diabetic patients].

  MMW Fortschritte der Medizin 20040805

• [Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice].

  MMW Fortschritte der Medizin 20040805

• Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy.

  The American journal of cardiology 20040801

• Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.

  Diabetes care 20040801

• AT1 receptor blockade alters metabolic, functional and structural proteins after reperfused myocardial infarction: detection using proteomics.

  Molecular and cellular biochemistry 20040801

• Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease.

  Journal of the American College of Cardiology 20040721

• Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis.

  Stroke 20040701

• Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.

  Hypertension (Dallas, Tex. : 1979) 20040701

• Irbesartan inhibits human T-lymphocyte activation through downregulation of activator protein-1.

  British journal of pharmacology 20040701

• Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives.

  Renal failure 20040701

• [Health economic aspects of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].

  Deutsche medizinische Wochenschrift (1946) 20040618

• Diverse effects of long-term treatment with imidapril and irbesartan on cell growth signal, apoptosis and collagen type I expression in the left ventricle of spontaneously hypertensive rats.

  Life sciences 20040611

• [A threat to cardiovascular risk patients. 'Activated renin-angiotensin system promotes end organ damage' (interview by Waldtraud Paukstadt)].

  MMW Fortschritte der Medizin 20040603

• Effects of differential blockade of the renin-angiotensin system in postinfarcted rats.

  Fundamental & clinical pharmacology 20040601

• ACE inhibitor and angiotensin type I receptor antagonist in combination reduce renal damage in obese Zucker rats.

  Kidney international 20040601

• Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria: response to Andersen, Brochner-Mortensen, and Parving.

  Diabetes care 20040601

• Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.

  The American journal of cardiology 20040601

• Enhanced platelet release of superoxide anion in systemic hypertension: role of AT1 receptors.

  Journal of hypertension 20040601

• Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study.

  Journal of hypertension 20040601

• Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension.

  Clinical cardiology 20040601

• Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries.

  Circulation 20040518

• Mesenteric artery remodeling and effects of imidapril and irbesartan on it in spontaneously hypertensive rats.

  World journal of gastroenterology 20040515

• Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.

  Circulation 20040504

• Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.

  Hypertension (Dallas, Tex. : 1979) 20040501

• Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20040501

• Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).

  Clinical cardiology 20040501

• AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction.

  Molecular and cellular biochemistry 20040501

• [Arterial hypertension in adipose patients. Rationale for a prospective medical care study in the family physician practice].

  MMW Fortschritte der Medizin 20040422

• Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.

  The Journal of pharmacology and experimental therapeutics 20040401

• Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat.

  Diabetes 20040401

• Effect of irbesartan on angiotensin II-induced hypertrophy of human proximal tubular cells.

  Chinese medical journal 20040401

• Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.

  Circulation 20040330

• Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity.

  Circulation 20040330

• Simultaneous determination of the acid/base antihypertensive drugs celiprolol, bisoprolol and irbesartan in human plasma by liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040305

• Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism.

  European journal of heart failure 20040301

• Clinical inquiries. Are ARBs or ACE inhibitors preferred for nephropathy in diabetes?

  The Journal of family practice 20040301

• Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

  Seminars in nephrology 20040301

• Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).

  Clinical cardiology 20040301

• What is the impact of PRIME on real-life diabetic nephropathy?

  International journal of clinical practice 20040301

• The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction.

  Cardiovascular research 20040215

• Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan.

  Journal of cardiovascular pharmacology 20040201

• Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion.

  Journal of cardiovascular pharmacology 20040201

• AT1 and AT2-receptor antagonists inhibit Ang II-mediated facilitation of noradrenaline release in human atria.

  Journal of cardiovascular pharmacology 20040201

• [Irbesartan-induced acute hepatitis].

  Gastroenterologia y hepatologia 20040201

• The KARTAN study: a postmarketing assessment of Irbesartan in patients with hypertension.

  Clinical therapeutics 20040201

• Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences.

  Journal of hypertension 20040201

• Irbesartan has a masking effect on dipyridamole stress induced myocardial perfusion defects.

  Nuclear medicine communications 20040201

• [Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage].

  MMW Fortschritte der Medizin 20040129

• [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].

  Deutsche medizinische Wochenschrift (1946) 20040102

• Pharmacokinetics and the cardiovascular effects of irbesartan in aortic coarctated rats.

  Pharmacology 20040101

• Hypersensitivity of the adrenal cortex to trophic and secretory effects of angiotensin II in Lyon genetically-hypertensive rats.

  Hypertension (Dallas, Tex. : 1979) 20040101

• Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.

  American journal of hypertension 20040101

• Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy.

  Atherosclerosis 20040101

• Role of reactive oxygen species-sensitive extracellular signal-regulated kinase pathway in angiotensin II-induced endothelin-1 gene expression in vascular endothelial cells.

  Journal of vascular research 20040101

• [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].

  Nihon rinsho. Japanese journal of clinical medicine 20040101

• Efforts to understand the molecular basis of hypertension through drug:membrane interactions.

  Current topics in medicinal chemistry 20040101

• Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada.

  The Canadian journal of cardiology 20040101

• Hypotensive and prophylactic effects of angiotensin II subtype 1 receptor antagonist, irbesartan, in stroke-prone spontaneously hypertensive rats.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20040101

• [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].

  Kardiologiia 20040101

• Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

  Drugs 20040101

• [Do generic drugs help control expenditure on hypertension? Apropos of a case].

  Gaceta sanitaria 20040101

• Metabolic and cardiovascular improvements after biliopancreatic diversion in a severely obese patient.

  Cardiovascular diabetology 20040101

• Signaling of angiotensin II-induced vascular protein synthesis in conduit and resistance arteries in vivo.

  BMC cardiovascular disorders 20040101

• [Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20040101

• Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.

  Clinical therapeutics 20040101

• Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.

  American journal of nephrology 20040101

• Effects of angiotensin II receptor blocker (irbesartan) on peritoneal membrane functions.

  Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 20040101

• Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment.

  BMC cardiovascular disorders 20040101

• Therapeutic effects of angiotensin (AT1) receptor antagonists: potential contribution of mechanisms other than AT1 receptor blockade.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20040101

• Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.

  Cardiovascular drug reviews 20040101

• [Antihypertensive and antiischemic effectiveness and safety of the AT1-receptor blocker irbesartranin arterial hypertension in patients with prior myocardial infarction].

  Klinicheskaia meditsina 20040101

• Regression of microalbuminuria in type 2 diabetics after switch to irbesartan treatment : an observational study in 38 016 patients in primary care.

  Clinical drug investigation 20040101

• Heart Rate Variability and Baroreflex Sensitivity during Fosinopril, Irbesartan and Atenolol Therapy in Hypertension.

  Clinical drug investigation 20040101

• Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.

  Diabetes care 20031201

• Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).

  Journal of cardiovascular pharmacology 20031201

• Demonstration of altered fibroblast contractile activity in hypertensive heart disease.

  Cardiovascular research 20031201

• Angiotensin II antagonists in the treatment of hypertension-effective and efficient?

  Herz 20031201

• Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.

  Clinical therapeutics 20031201

• Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis.

  Journal of the American Society of Nephrology : JASN 20031101

• Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.

  American journal of hypertension 20031101

• Role of systolic blood pressureon the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity, and hypertension (Zucker rats).

  American journal of hypertension 20031101

• Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy.

  Journal of cardiovascular pharmacology 20031101

• Recommendations for the management of special populations: renal disease in diabetes.

  American journal of hypertension 20031101

• Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension.

  Clinical therapeutics 20031101

• [Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats].

  Zhonghua er ke za zhi = Chinese journal of pediatrics 20031101

• [Dosage equivalents of AT1-receptor antagonists available in Germany].

  Deutsche medizinische Wochenschrift (1946) 20031031

• [Prospective treatment study of irbesartan. Diabetic kidneys regain function].

  MMW Fortschritte der Medizin 20031009

• [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].

  MMW Fortschritte der Medizin 20031009

• Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood.

  Kidney international 20031001

• An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20031001

• Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrations.

  Journal of hypertension 20031001

• Some recent randomized clinical trials in the management of atrial fibrillation.

  Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20031001

• [Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology].

  Orvosi hetilap 20030907

• Study of the hypothalamic angiotensin system in aortic coarctated rats using the reverse microdialysis technique.

  Pharmacological research 20030901

• Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes.

  Expert opinion on pharmacotherapy 20030901

• Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues.

  Journal of cardiovascular electrophysiology 20030901

• Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat.

  Journal of cardiovascular pharmacology and therapeutics 20030901

• [ACE inhibitors and/or sartans in heart failure: is there a difference?].

  Revue medicale de Bruxelles 20030901

• Comparative effects of tamoxifen and angiotensin II type-1 receptor antagonist therapy on the hemodynamic profile of the ovariectomized female rat.

  Canadian journal of physiology and pharmacology 20030901

• Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial.

  Cardiac electrophysiology review 20030901

• Lessons from trials in hypertensive type 2 diabetic patients.

  Current hypertension reports 20030801

• Do irbesartan and amlodipine reduce cardiovascular events in diabetic patients?

  The Journal of family practice 20030801

• Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog.

  Cardiovascular research 20030801

• [Effects of irbesartan on remodeling of the left ventricular following acute myocardial infarction].

  Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue 20030801

• Three new spectrophotometric methods applied to the simultaneous determination of hydrochlorothiazide and irbesartan.

  Die Pharmazie 20030801

• The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective.

  Minerva medica 20030801

• Effects of angiotensin II type 1 receptor blockade in ApoE-deficient mice with post-ischemic heart failure.

  Journal of cardiovascular pharmacology 20030701

• Functional comparison of the antagonistic properties of some Angiotensin II type 1 receptor blockers on the contraction elicited by Angiotensin II and thromboxane A2 on human saphenous veins.

  Journal of cardiovascular pharmacology 20030701

• Influence of two doses of irbesartan on non-dipper circadian blood pressure rhythm in salt-sensitive black hypertensives under high salt diet.

  Journal of cardiovascular pharmacology 20030701

• Exanthematous reaction to irbesartan.

  Journal of the European Academy of Dermatology and Venereology : JEADV 20030701

• Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology.

  British journal of clinical pharmacology 20030701

• [Antihypertensive therapy in renal dysfunction].

  Nihon rinsho. Japanese journal of clinical medicine 20030701

• The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.

  Clinical therapeutics 20030701

• Cardiology patient page. Angiotensin receptor blockers.

  Circulation 20030624

• Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray.

  World journal of gastroenterology 20030615

• [Fast-acting sartan. High blood pressure therapy without long waiting time].

  MMW Fortschritte der Medizin 20030612

• Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.

  Journal of medicinal chemistry 20030605

• Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1.

  The Journal of pharmacology and experimental therapeutics 20030601

• Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis.

  Kidney international 20030601

• Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan.

  Cardiovascular research 20030601

• No involvement of the AT2-receptor in angiotensin II-enhanced sympathetic transmission in vitro.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20030601

• Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.

  The American journal of cardiology 20030522

• [Diurnal blood pressure control in the optimal treatment of hypertension].

  Orvosi hetilap 20030504

• Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

  Kidney international 20030501

• Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease.

  The American journal of cardiology 20030501

• The true overall mortality of unselected nephropathic type 2 diabetic patients with mild to moderate renal insufficiency.

  Diabetes care 20030501

• Treatment with irbesartan counteracts the functional remodeling of ventricular myocytes from hypertensive rats.

  Journal of cardiovascular pharmacology 20030501

• Outcome studies in diabetic nephropathy.

  Seminars in nephrology 20030501

• [Influence of irbesartan on renal hypertrophy and thickening of glomerular basement-membrane in streptozotocin-induced diabetic rats].

  Zhonghua nei ke za zhi 20030501

• AT1-receptor antagonism in hypertension: what has been learned with irbesartan?

  Expert review of cardiovascular therapy 20030501

• [Dangerous deficits in management of hypertensive diabetic patients. A kidney check is far from standard procedure].

  MMW Fortschritte der Medizin 20030424

• A two-state model of antagonist-AT1 receptor interaction: further support by binding studies at low temperature.

  Biochemical pharmacology 20030415

• Validation of a new intraarterial microdialysis shunt probe for the estimation of pharmacokinetic parameters.

  Journal of pharmaceutical and biomedical analysis 20030410

• Induction of MIF synthesis and secretion by tubular epithelial cells: a novel action of angiotensin II.

  Kidney international 20030401

• Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled study.

  Journal of hepatology 20030401

• Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

  Annals of internal medicine 20030401

• Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.

  Annals of internal medicine 20030401

• [Effect of anti-hypertensive therapy with irbesartan on the absolute cardiovascular risk].

  Revista clinica espanola 20030401

• AT1 receptor antagonist therapy preferentially ameliorated right ventricular function and phenotype during the early phase of remodeling post-MI.

  British journal of pharmacology 20030401

• Pretreatment of patients with atrial fibrillation who undergo electrical cardioversion.

  Circulation 20030325

• Discovery of 4'-[(imidazol-1-yl)methyl]biphenyl-2-sulfonamides as dual endothelin/angiotensin II receptor antagonists.

  Bioorganic & medicinal chemistry letters 20030324

• Control of dendritic cell differentiation by angiotensin II.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030301

• Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study.

  Diabetes care 20030301

• Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure.

  Cardiovascular research 20030301

• B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.

  Journal of hypertension 20030301

• Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

  Clinical and experimental nephrology 20030301

• Simultaneous determination of hydrochlorothiazide and several angiotensin-II-receptor antagonists by capillary electrophoresis.

  Journal of pharmaceutical and biomedical analysis 20030226

• Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II.

  Journal of the American College of Cardiology 20030219

• Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization.

  The Journal of pharmacology and experimental therapeutics 20030201

• Angiotensin II AT1 receptor blockade improves renal perfusion in hypercholesterolemia.

  American journal of hypertension 20030201

• Sympatho-inhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar-Kyoto rats.

  Fundamental & clinical pharmacology 20030201

• Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030125

• Optimization and validation of a micellar electrokinetic chromatographic method for the analysis of several angiotensin-II-receptor antagonists.

  Journal of chromatography. A 20030110

• Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan.

  PharmacoEconomics 20030101

• Olmesartan medoxomil: the seventh angiotensin receptor antagonist.

  The Annals of pharmacotherapy 20030101

• Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats.

  Acta pharmacologica Sinica 20030101

• A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response.

  Pharmacogenetics 20030101

• Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives.

  Drug safety 20030101

• [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].

  Kardiologiia 20030101

• Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy.

  BMC cardiovascular disorders 20030101

• Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients.

  British journal of biomedical science 20030101

• Optimization and validation of a capillary zone electrophoretic method for the analysis of several angiotensin-II-receptor antagonists.

  Journal of chromatography. A 20021206

• Angiotensin blockade in type 2 diabetic renal disease.

  Kidney international. Supplement 20021201

• Irbesartan substitution for valsartan or losartan in treating hypertension.

  The Annals of pharmacotherapy 20021201

• Acute pancreatitis associated with angiotensin II receptor antagonists.

  The Annals of pharmacotherapy 20021201

• Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases.

  American journal of hypertension 20021201

• Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.

  Hypertension (Dallas, Tex. : 1979) 20021201

• Factors influencing acute ischaemia-induced renal hypertension in rats.

  Journal of hypertension 20021201

• Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.

  The Canadian journal of cardiology 20021201

• Irbesartan-associated persistent edema of the eyelids, face, and neck.

  Journal of drugs in dermatology : JDD 20021201

• Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).

  The American journal of cardiology 20021115

• [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

  Presse medicale (Paris, France : 1983) 20021109

• Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.

  Diabetes care 20021101

• Proteinuria as a predictor of total plasma homocysteine levels in type 2 diabetic nephropathy.

  Diabetes care 20021101

• Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?

  Journal of hypertension 20021101

• [Effect of angiotensin blockade on the orthostatic response in patients with systemic arterial hypertension].

  Revista espanola de cardiologia 20021101

• Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers.

  Journal of the American Society of Nephrology : JASN 20021101

• Pharmacologic management of diabetic nephropathy.

  Clinical therapeutics 20021101

• [Comparison of the antihypertensive activity of fosinopril and irbesartan].

  Anales de medicina interna (Madrid, Spain : 1984) 20021101

• Antagonist interaction with endogenous AT(1) receptors in human cell lines.

  Biochemical pharmacology 20021015

• Comparison of 3D structures and AT(1) binding properties of pyrazolidine-3,5-diones and tetrahydropyridazine-3,6-diones with parent antihypertensive drug irbesartan.

  Journal of medicinal chemistry 20021010

• Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome.

  The Journal of pharmacology and experimental therapeutics 20021001

• Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan.

  Diabetic medicine : a journal of the British Diabetic Association 20021001

• The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.

  Journal of hypertension 20021001

• Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade.

  American journal of hypertension 20021001

• The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes.

  American journal of hypertension 20021001

• [Tendency and prospect of the development of new ARBs].

  Nihon rinsho. Japanese journal of clinical medicine 20021001

• [Large scale clinical trials in prevention of end-stage renal disease due to type 2 diabetes with angiotensin receptor antagonists].

  Nihon rinsho. Japanese journal of clinical medicine 20021001

• [Diabetic nephropathy].

  Nihon rinsho. Japanese journal of clinical medicine 20021001

• [Evidence based treatment of diabetic nephropathy].

  Nihon rinsho. Japanese journal of clinical medicine 20021001

• [Evidence for the benefits of ACE inhibitors and AII antagonists in slowing progressive renal failure in diabetes].

  Nihon rinsho. Japanese journal of clinical medicine 20021001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021001

• [Sartan improves anti-arrhythmia therapy after cardioversion. Fewer recurrent fibrillation incidents].

  MMW Fortschritte der Medizin 20020912

• In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist.

  The Journal of pharmacology and experimental therapeutics 20020901

• Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta.

  Journal of hypertension 20020901

• [What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• Involvement of the AT(2)-receptor in angiotensin II-induced facilitation of sympathetic neurotransmission.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20020901

• Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.

  Journal of medicinal chemistry 20020829

• AT(1)-receptor blockers: differences that matter.

  Journal of human hypertension 20020801

• A population-based European cohort study of persistence in newly diagnosed hypertensive patients.

  Journal of human hypertension 20020801

• Cardiac autonomic tone during trandolapril-irbesartan low-dose combined therapy in hypertension: a pilot project.

  Journal of human hypertension 20020801

• AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20020801

• Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.

  Hypertension (Dallas, Tex. : 1979) 20020801

• Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study.

  Journal of hypertension 20020801

• Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension.

  Journal of hypertension 20020801

• Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade.

  Journal of hypertension 20020801

• Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity.

  European journal of gastroenterology & hepatology 20020801

• [Effect of astragalus-angelica mixture on osteopontin expression in rats with chronic nephrosclerosis].

  Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20020801

• Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.

  Circulation 20020716

• Renal microvascular actions of angiotensin II fragments.

  American journal of physiology. Renal physiology 20020701

• Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension.

  Cardiovascular research 20020701

• Pharmacokinetics of irbesartan are not altered in special populations.

  Journal of cardiovascular pharmacology 20020701

• Recent landmark clinical trials: how do they modify the therapeutic paradigm?

  American journal of hypertension 20020701

• Angiotensin II type 1 receptors and oestrogen status: interaction or dissociation?

  Journal of hypertension 20020701

• Angiotensin II type 1 receptor blocker irbesartan ameliorates vascular function in spontaneously hypertensive rats regardless of oestrogen status.

  Journal of hypertension 20020701

• The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.

  Clinical therapeutics 20020701

• Determination of irbesartan in the presence of hydrochlorothiazide by derivative spectrophotometry.

  Journal of pharmaceutical and biomedical analysis 20020620

• [ACE inhibitor or AT1 antagonist. Is there a differential therapy?].

  MMW Fortschritte der Medizin 20020613

• Comparison of the vascular and antiadrenergic activities of four angiotensin II type 1 antagonists in the pithed rat.

  Journal of hypertension 20020601

• Vasopressin-induced presynaptic facilitation of sympathetic neurotransmission in the pithed rat.

  Journal of hypertension 20020601

• Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors.

  Diabetes 20020601

• Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020601

• Molecular mobility study of amorphous and crystalline phases of a pharmaceutical product by thermally stimulated current spectrometry.

  Journal of pharmaceutical sciences 20020601

• Gateways to Clinical Trials. June 2002.

  Methods and findings in experimental and clinical pharmacology 20020601

• Sympatho-inhibitory properties of various AT1 receptor antagonists.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20020601

• [Irbesartan: a new possibility in the treatment of hypertension].

  Orvosi hetilap 20020526

• Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterol-fed rabbits.

  European journal of pharmacology 20020503

• Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.

  Expert opinion on pharmacotherapy 20020501

• Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.

  American journal of hypertension 20020501

• Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.

  The Canadian journal of cardiology 20020501

• Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.

  The Canadian journal of cardiology 20020501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20020501

• Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog.

  Journal of the American College of Cardiology 20020417

• Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.

  Journal of cardiovascular pharmacology 20020401

• Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.

  Journal of hypertension 20020401

• An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.

  Blood pressure monitoring 20020401

• Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection.

  Journal of chromatography. A 20020308

• Angiotensin II infusion ameliorates the early phase of a mesangioproliferative glomerulonephritis.

  Kidney international 20020301

• Angiotensin II subtype 1 (AT1) receptors contribute to ischemic contracture and regulate chemomechanical energy transduction in isolated transgenic rat (alphaMHC-hAT1)594-17 hearts.

  European journal of heart failure 20020301

• Angiotensin II receptor antagonists role in arterial hypertension.

  Journal of human hypertension 20020301

• Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety.

  Pharmacoepidemiology and drug safety 20020301

• Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.

  The New England journal of medicine 20020227

• Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.

  The New England journal of medicine 20020227

• [Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].

  MMW Fortschritte der Medizin 20020221

• Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment.

  Circulation 20020205

• Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats.

  Journal of hypertension 20020201

• Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout.

  Journal of hypertension 20020201

• Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia.

  European journal of pharmacology 20020201

• Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension.

  Digestive diseases and sciences 20020201

• Increased angiotensin II-mediated Src signaling via epidermal growth factor receptor transactivation is associated with decreased C-terminal Src kinase activity in vascular smooth muscle cells from spontaneously hypertensive rats.

  Hypertension (Dallas, Tex. : 1979) 20020201

• Additional effects of irbesartan when compared to captopril in the prevention of post-infarction left ventricular dilatation.

  Acta cardiologica 20020201

• Current recommendations for the treatment of hypertension: are they still valid?

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20020201

• [Angiotensin 2 receptor blockaders: how do we explain the kidney-protective effect?].

  Lakartidningen 20020110

• Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo.

  The Journal of pharmacology and experimental therapeutics 20020101

• Vasoconstriction is determined by interstitial rather than circulating angiotensin II.

  British journal of pharmacology 20020101

• Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.

  Journal of hypertension 20020101

• Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.

  Journal of hypertension 20020101

• Increased osteopontin expression following renal ablation is attenuated by angiotensin type 1 receptor antagonism.

  Experimental nephrology 20020101

• Angiotensin II-induced drinking and pressor responses to central or systemic irbesartan and losartan.

  Pharmacology, biochemistry, and behavior 20020101

• Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options.

  Journal of clinical hypertension (Greenwich, Conn.) 20020101

• Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.

  Clinical pharmacology and therapeutics 20020101

• Preventing nephropathy in patients with type 2 diabetes.

  Managed care interface 20020101

• A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).

  Clinical therapeutics 20020101

• Application of capillary zone electrophoresis to the screening of some angiotensin II receptor antagonists.

  Electrophoresis 20020101

• Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?

  Drug safety 20020101

• [The best of 2001. Arterial hypertension].

  Archives des maladies du coeur et des vaisseaux 20020101

• Lack of impairment of nitric oxide-mediated responses in a rat model of high-renin hypertension.

  Clinical and experimental pharmacology & physiology 20020101

• [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data].

  La Clinica terapeutica 20020101

• Irbesartan was renoprotective in patients with type 2 diabetes, hypertension, and microalbuminuria.

  ACP journal club 20020101

• Irbesartan reduced progression of nephropathy caused by type 2 diabetes independent of the effect on blood pressure.

  ACP journal club 20020101

• Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan.

  Blood pressure 20020101

• Olmesartan medoxomil.

  Drugs 20020101

• Losartan and diabetic nephropathy: commentaries on the RENAAL study.

  Cardiovascular diabetology 20020101

• [Effect of irbesartan, an antagonist of AT-1 receptors for angiotensin II, on L-arginine metabolism in arterial hypertension].

  Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994) 20020101

• [Enalapril and irbesartan in treatment of patients with arterial hypertension].

  Likars'ka sprava 20020101

• [Effect of angiotensin receptor blockers on hemodynamic aspects during myocardial infarction].

  Likars'ka sprava 20020101

• [Irbesartan--antihypertensive treatment in patients with heart failure and diabetes mellitus].

  Przeglad lekarski 20020101

• [Role of angiotensin II antagonists in the treatment of hypertension].

  Medicinski arhiv 20020101

• EC approves irbesartan for the treatment of diabetic renal disease.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20020101

• Evaluation of irbesartan effects as a function of the time of drug administration.

  Proceedings of the Western Pharmacology Society 20020101

• [Cross-sensitivity between angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonist].

  Annales de dermatologie et de venereologie 20020101

• The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy.

  Blood pressure 20020101

• A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?

  Congestive heart failure (Greenwich, Conn.) 20020101

• [Clinical hypertensiology: analysis of trials completed in 2001-2002].

  Kardiologiia 20020101

• Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.

  Annals of medicine 20020101

• [Effect of irbesartan--angiotensin II type I receptor inhibitor on oxidative metabolism of lipids in essential hypertension].

  Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994) 20020101

• Study on the pharmacokinetics and relative bioavailability of irbesartan capsules in healthy volunteers.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20020101

• AVAPROMISE: A randomized clinical trial for increasing adherence through behavioural modification in essential hypertension.

  Experimental and clinical cardiology 20020101

• AT(2) receptor-mediated vasodilation in the heart: effect of myocardial infarction.

  American journal of physiology. Heart and circulatory physiology 20011201

• The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.

  Journal of human hypertension 20011201

• Coronary dilatation reserve in experimental hypertension and chronic heart failure: effects of blockade of the renin-angiotensin system.

  Clinical and experimental pharmacology & physiology 20011201

• Angiotensin receptor blockers in diabetic nephropathy.

  Current diabetes reports 20011201

• Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease.

  Journal of the American College of Cardiology 20011115

• Influence of irbesartan and enalapril on changes of renal function associated with the established phase of l-NAME hypertension.

  Journal of hypertension 20011101

• Drug companies should not have the final say in the design of clinical trials.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20011101

• Angiotensin II receptor blockers for the treatment of hypertension.

  Expert opinion on pharmacotherapy 20011101

• Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.

  The Medical journal of Australia 20011015

• Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans.

  Circulation 20011009

• [Irbesartan in hypertension. A plus for therapy compliance].

  MMW Fortschritte der Medizin 20011004

• pK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry.

  Journal of pharmaceutical and biomedical analysis 20011001

• Angiotensin II receptor blockers and nephropathy trials.

  Diabetes care 20011001

• A clinical trial in type 2 diabetic nephropathy.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20011001

• Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.

  Journal of hypertension 20011001

• Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.

  Journal of hypertension 20011001

• Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.

  Journal of hypertension 20011001

• Relation between clinical and therapeutic variables and quality of life in hypertension.

  Journal of hypertension 20011001

• [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].

  Ugeskrift for laeger 20011001

• Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats.

  Hypertension (Dallas, Tex. : 1979) 20011001

• [Clinical study of the month. Nephroprotective role of angiotensin II receptor antagonists in type 2 diabetes: results of the IDNT and RENAAL trials].

  Revue medicale de Liege 20011001

• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  The New England journal of medicine 20010920

• The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

  The New England journal of medicine 20010920

• Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice.

  Journal of cardiovascular pharmacology 20010901

• Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.

  Journal of cardiovascular pharmacology 20010901

• Impact of the renin-angiotensin system on cerebral perfusion following subarachnoid haemorrhage in the rat.

  The Journal of physiology 20010901

• The pharmacokinetics and pharmacodynamics of irbesartan in heart failure.

  Journal of clinical pharmacology 20010901

• Angiotensin II-induced apoptosis in rat cardiomyocyte culture: a possible role of AT1 and AT2 receptors.

  Journal of hypertension 20010901

• Differentiation in the angiotensin II receptor 1 blocker class on autonomic function.

  Current hypertension reports 20010901

• Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis.

  Journal of hepatology 20010901

• Adenovirus-mediated overexpression and stimulation of the human angiotensin II type 2 receptor in porcine cardiac fibroblasts does not modulate proliferation, collagen I mRNA expression and ERK1/ERK2 activity, but inhibits protein tyrosine phosphatases.

  Journal of molecular medicine (Berlin, Germany) 20010901

• Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20010901

• [Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].

  MMW Fortschritte der Medizin 20010809

• Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension.

  Gastroenterology 20010801

• Acute oliguric renal failure associated with angiotensin II receptor antagonists.

  The American journal of medicine 20010801

• Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.

  Journal of cardiovascular pharmacology 20010701

• The pharmacokinetics of irbesartan in hypertensive children and adolescents.

  Journal of clinical pharmacology 20010701

• Insurmountable AT(1) receptor antagonism: the need for different antagonist binding states of the receptor.

  Trends in pharmacological sciences 20010701

• Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.

  International journal of cardiology 20010701

• Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension.

  Diabetologia 20010701

• Angiotensin II subtype 1 receptor blockers and renal function.

  Archives of internal medicine 20010625

• Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats.

  Clinical science (London, England : 1979) 20010601

• Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism.

  Journal of hypertension 20010601

• Regression of left ventricular hypertrophy in human hypertension with irbesartan.

  Journal of hypertension 20010601

• Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists.

  Bioorganic & medicinal chemistry 20010601

• [Angiotensin II receptor antagonists: different or equivalent?].

  Presse medicale (Paris, France : 1983) 20010601

• [Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].

  MMW Fortschritte der Medizin 20010531

• Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure.

  Circulation 20010501

• Angiotensin II type I receptor modulates intracellular free Mg2+ in renally derived cells via Na+-dependent Ca2+-independent mechanisms.

  The Journal of biological chemistry 20010427

• Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion.

  Swiss medical weekly 20010407

• The peripheral renin-angiotensin system is not involved in the hypertension of sheep exposed to prenatal dexamethasone.

  Clinical and experimental pharmacology & physiology 20010401

• [Angioedema due to irbesartan].

  Revista espanola de cardiologia 20010401

• Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.

  Journal of cardiovascular pharmacology 20010401

• Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.

  Postgraduate medicine 20010401

• Obese female SHHF/Mcc-fa(cp) rats resist antihypertensive effects of renin-angiotensin system inhibition.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20010401

• Drug-induced cholestasis.

  Seminars in gastrointestinal disease 20010401

• Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries.

  Fundamental & clinical pharmacology 20010401

• Headache, hypertension, and irbesartan therapy.

  Archives of internal medicine 20010312

• Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade.

  Hypertension (Dallas, Tex. : 1979) 20010301

• Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?

  Cleveland Clinic journal of medicine 20010301

• Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril.

  Journal of hypertension 20010301

• Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activated-protein kinase by AT1 receptors in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats.

  Journal of hypertension 20010301

• The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo.

  Journal of hypertension 20010301

• Apoptosis and changes in contractile protein pattern in the skeletal muscle in heart failure.

  Acta physiologica Scandinavica 20010301

• Angiotensin II type 1 receptor blockers.

  Circulation 20010213

• A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.

  Biochemical pharmacology 20010201

• Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis.

  Journal of the American College of Cardiology 20010201

• p38 Map kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY.

  Hypertension (Dallas, Tex. : 1979) 20010201

• Left ventricular hypertrophy and angiotensin II antagonists.

  American journal of hypertension 20010201

• Treatment of psychogenic polydipsia: comparison of risperidone and olanzapine, and the effects of an adjunctive angiotensin-II receptor blocking drug (irbesartan).

  The Australian and New Zealand journal of psychiatry 20010201

• Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats.

  Circulation 20010123

• ACE inhibitor and AT1 antagonist blockade of deformation-induced gene expression in the rabbit jugular vein through B2 receptor activation.

  Arteriosclerosis, thrombosis, and vascular biology 20010101

• Differential effects of enalapril and irbesartan in experimental papillary necrosis.

  Kidney & blood pressure research 20010101

• Drug interaction: omeprazole and phenprocoumon.

  BMC gastroenterology 20010101

• The comparative pharmacology of angiotensin II receptor antagonists.

  Blood pressure. Supplement 20010101

• Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010101

• Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010101

• Angiotensin II AT(1) receptor antagonists and platelet activation.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010101

• Vasoconstrictive drugs increase carbonic anhydrase I in vascular smooth muscle while vasodilating drugs reduce the activity of this isozyme by a direct mechanism of action.

  Drugs under experimental and clinical research 20010101

• Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension.

  Drugs 20010101

• Pharmacological differences among angiotensin II receptor antagonists.

  Blood pressure. Supplement 20010101

• Clinical differences among angiotensin II receptor antagonists.

  Blood pressure. Supplement 20010101

• Hypertension and diabetes: the scope of the problem.

  Blood pressure. Supplement 20010101

• Irbesartan achieves consistent and effective use over 1 year.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20010101

• New stuff about the diabetic kidney.

  Journal of clinical hypertension (Greenwich, Conn.) 20010101

• [Effects of inhibitors of angiotensin-converting enzyme combined with antagonists of angiotensin II receptors on endothelial function in patients with chronic cardiac insufficiency].

  Likars'ka sprava 20010101

• [Choosing the dose of aprovel (irbesartan) in patients with chronic heart insufficiency].

  Klinicheskaia meditsina 20010101

• Drug interactions with irbesartan.

  Clinical pharmacokinetics 20010101

• Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.

  Journal of clinical hypertension (Greenwich, Conn.) 20010101

• [Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20010101

• Clinical comparative trials of angiotensin II type 1 (AT1)-receptor blockers.

  Blood pressure. Supplement 20010101

• The relationship between dose and antihypertensive effect for different AT1-receptor blockers.

  Blood pressure. Supplement 20010101

• Pharmacology of AT1-receptor blockers.

  Blood pressure. Supplement 20010101

• Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20010101

• Irbesartan slows the development of diabetic nephropathy by up to 70% in hypertensive diabetic patients.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20010101

• End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency.

  Renal failure 20001101

• Binding characteristics of [(3)H]-irbesartan to human recombinant angiotensin type 1 receptors.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20000601

• The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20000401

• Protease inhibitors: current status and future prospects.

  Journal of medicinal chemistry 20000210

• A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group.

  International journal of clinical practice 20000101

• Irbesartan: review of pharmacology and comparative properties.

  The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 20000101

• The mechanism of action of angiotensin II is dependent on direct activation of vascular smooth muscle carbonic anhydrase I.

  International journal of clinical & laboratory research 20000101

• ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy.

  The American journal of physiology 19990301

• Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.

  Hypertension (Dallas, Tex. : 1979) 19990301

• Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.

  British journal of pharmacology 19990201

• The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.

  Journal of the American Society of Nephrology : JASN 19981201

• Anaemia in dialysis patients as a side-effect of sartanes.

  Lancet (London, England) 19980725

• Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus.

  Kidney international. Supplement 19971201

• Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 19971201

• Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis.

  Circulation 19970318

• Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.

  Journal of medicinal chemistry 19960202